Document:

EX-4.2

 Exhibit 4.2 

EXECUTION VERSION 
 SILVERBACK
THERAPEUTICS, INC. 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made as of September 22, 2020
(the “Effective Date”), by and among Silverback Therapeutics, Inc., a Delaware corporation (the “Company”), the persons and entities listed on Exhibit A hereto (each, an
“Investor” and collectively, the “Investors”). 
 RECITALS 

A. The Company and certain of the Investors have entered into that certain Series C Preferred Stock Purchase Agreement of even date
herewith (as the same may be amended and restated from time to time, the “Series C Purchase Agreement”), which provides for, among other things, the purchase by the Investors of shares of the Company’s Series C Preferred
Stock, par value $0.0001 per share (the “Series C Preferred Stock”); 
 B. A condition to the obligations of
such Investors under the Series C Purchase Agreement to purchase the Series C Preferred Stock is that the Company and the Investors enter into this Agreement; 

C. The Company and those Investors who own shares of the Company’s Series B Preferred Stock, par value $0.0001 per share (the
“Series B Preferred Stock”) and, in certain cases also own shares of the Company’s Series A Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), are party to that certain
Amended and Restated Investors’ Rights Agreement, dated as of March 4, 2020 (the “Prior Agreement”); and 

D. In order to further induce the Investors to purchase the Series C Preferred Stock, the undersigned Investors who own shares of the
Company’s Series B Preferred Stock and Series A Preferred Stock and the Company desire to amend and restate in its entirety the Prior Agreement and to accept the rights and obligations created pursuant hereto in lieu of their rights and
obligations under the Prior Agreement. 
 NOW, THEREFORE, in consideration of the mutual promises and covenants set forth
herein, and certain other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 

1. Definitions. As used in this Agreement, the following terms shall have the meanings set forth below: 

(a) “Affiliate” means, with respect to any specified person or entity, any other person or entity who, directly
or indirectly, controls, is controlled by, or is under common control with such person or entity, including without limitation any general partner, managing member, officer, principal, director or trustee of such party, or any venture capital fund,
registered investment company, investment fund, managed investment account or other fund now or hereafter existing that is controlled by one or more general partners, managing members or 

 
investment advisers of, or shares the same management or advisory company (or stockholder or member thereof) or investment adviser with, such person or entity; provided that with respect to a
person or entity that is either an individual or an irrevocable or revocable trust established for such individual or for such individual and such individual’s family, spouse or domestic partner, an “Affiliate” shall mean a family
member, spouse or domestic partner of such individual, and includes, in the case of a trust, such individual. 
 (b)
“Board” means the Company’s Board of Directors. 
 (c) “CFIUS” the Committee on
Foreign Investment in the United States. 
 (d) “CFIUS Investor” means any Investor to the extent that, in
connection with the exercise of such Investor’s right of first refusal pursuant to Section 4 below a notice or declaration is required to be filed with CFIUS. 

(e) “Commission” means the Securities and Exchange Commission or any other federal agency at the time
administering the Securities Act. 
 (f) “Common Stock” means the Common Stock, par value $0.0001 per share,
of the Company. 
 (g) “Election Period” shall have the meaning set forth in
Section 4.4 hereof. 
 (h) “Excess Securities” shall have the meaning set forth in
Section 4.4 hereof. 
 (i) “Exchange Act” means the Securities Exchange Act of
1934, as amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time. 

(j) “Fund” shall have the meaning set forth in Section 3.3 hereof. 

(k) “Holder” means any Investor who holds Registrable Securities and any other holder of Registrable Securities
to whom the registration rights conferred by this Agreement have been duly and validly transferred in accordance with Section 2.12 of this Agreement. 

(l) “Indemnified Party” shall have the meaning set forth in Section 2.6(c) hereof.

 (m) “Indemnifying Party” shall have the meaning set forth in Section 2.6(c)
hereof. 
 (n) “initial Public Offering” means the closing of the Company’s first bona fide, firm commitment
underwritten public offering of the Company’s Common Stock registered under the Securities Act. 
 (o) “Initiating
Holders” means any Holder or Holders who in the aggregate hold not less than thirty percent (30%) of the Registrable Securities then outstanding. 

  
 2 

 (p) “Liquidation Event” shall have the meaning set forth in
the Company’s Restated Certificate. 
 (q) “Major Investor” means any Investor that holds not less than
2,900,000 shares of Series C Preferred Stock or not less than 1,500,000 shares of Series A Preferred Stock and Series B Preferred Stock, on a combined basis, as shall be adjusted for any stock splits, stock dividends, combinations, subdivisions,
recapitalizations or the like with respect to such applicable series of Preferred Stock. For clarity, at such time as any Investor who previously held the requisite number of shares of Preferred Stock set forth above in this subsection (q) no
longer holds at least such amount of Preferred Stock, such Investor shall lose its status as a Major Investor. 
 (r) “New
Securities” shall have the meaning set forth in Section 4.2 hereof. 
 (s) “Other
Selling Stockholders” means persons other than Holders who, by virtue of agreements with the Company, are entitled to include their Other Shares in certain registrations hereunder. 

(t) “Other Shares” means shares of Common Stock, other than Registrable Securities with respect to which
registration rights have been granted. 
 (u) “Preferred Director” shall have the meaning set forth in the
Restated Certificate. 
 (v) “Preferred Majority” means the holders in the aggregate of a majority of the
then outstanding shares of Preferred Stock, voting together as a single class, on as converted to Common Stock basis. 
 (w)
“Preferred Stock” means, collectively, all shares of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and any other shares of Preferred Stock of the Company whether or not authorized as of the
Effective Date. 
 (x) “Pro Rata Amount” shall have the meaning set forth in
Section 4.1 hereof. 
 (y) “Qualified Public Offering” shall have the meaning set
forth in the Restated Certificate. 
 (z) “Registrable Securities” means (i) shares of Common Stock
issued or issuable pursuant to the conversion of the Shares, (ii) any shares of Common Stock, or any shares of Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, in
each case, acquired by the Investors after the date hereof, and (iii) any shares of Common Stock issued as a dividend or other distribution with respect to or in exchange for or in replacement of the shares referenced in (i) or (ii) above;
provided, however, that Registrable Securities shall not include any shares of Common Stock described in clauses (i), (ii) or (iii) above which have been sold to the public either pursuant to a registration statement or Rule 144,
or which have been sold in a private transaction in which the transferor’s rights under this Agreement are not validly assigned in accordance with this Agreement; and provided, further, however, that Registrable Securities
shall not include any shares of Common Stock described in clauses (i), (ii) or (iii) above as to which rights have terminated pursuant to Section 2.14 hereof. 

  
 3 

 (aa) “Registrable Securities then outstanding” means the
number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible
securities that are Registrable Securities. 
 (bb) The terms “register,”
“registered” and “registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act and applicable rules and regulations thereunder,
and the declaration or ordering of the effectiveness of such registration statement. 
 (cc) “Registration
Expenses” means all expenses incurred in effecting any registration pursuant to this Agreement or an Initial Public Offering, including, without limitation, all registration, qualification, and filing fees, printing expenses, escrow
fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one special counsel for the Holders (selected by the Holders of a majority of the Registrable Securities to be registered) (in each case, not to
exceed $35,000), blue sky fees and expenses, and expenses of any regular or special audits incident to or required by any such registration, but shall not include Selling Expenses, fees and disbursements of other counsel for the Holders and the
compensation of regular employees of the Company, which shall be paid in any event by the Company. 
 (dd) “Restated
Certificate” means the Company’s Amended and Restated Certificate of Incorporation (as may be amended or restated from time to time). 

(ee) “Restricted Securities” means any Registrable Securities required to bear the first legend set forth in
Section 2.8(c) hereof. 
 (ff) “ROFR Holder” shall have the meaning set forth in
Section 4.1 hereof. 
 (gg) “Rule 144” means Rule 144 as promulgated by the
Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. 

(hh) “Rule 145” means Rule 145 as promulgated by the Commission under the Securities Act, as such Rule may be
amended from time to time, or any similar successor rule that may be promulgated by the Commission. 
 (ii) “Rule
415” means Rule 415 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. 

  
 4 

 (jj) “Securities Act” means the Securities Act of 1933, as
amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time. 

(kk) “Selling Expenses” means all underwriting discounts, selling commissions and stock transfer taxes
applicable to the sale of Registrable Securities and fees and disbursements of counsel for any Holder (other than the fees and disbursements of one special counsel to the Holders included in Registration Expenses). 

(ll) “Series A Preferred Stock” shall have the meaning ascribed thereto in the Recitals hereof. 

(mm) “Series B Preferred Stock” shall have the meaning ascribed thereto in the Recitals hereof. 

(nn) “Series C Purchase Agreement” shall have the meaning ascribed thereto in the Recitals hereof. 

(oo) “Shares” means the Preferred Stock. 

(pp) “Voting Agreement” means that certain Amended and Restated Voting Agreement entered into by and among the
Company and the Stockholders named therein as of even date herewith, as such may be amended or restated from time to time in accordance with the provisions thereof 

(qq) “Withdrawn Registration” means a forfeited demand registration under Section 2.1
in accordance with the terms and conditions of Section 2.4. 
 2. Registration Rights. 

2.1 Requested Registration. 

(a) Registration. Subject to the conditions set forth in this Section 2.1, if the Company shall
receive from Initiating Holders a written request signed by such Initiating Holders that the Company effect any registration with respect to all or a part of the Registrable Securities (such request shall state the number of shares of Registrable
Securities proposed to be disposed of by such Initiating Holders), the Company will: 
 (i) promptly give written notice of the proposed
registration to all other Holders; and 
 (ii) as soon as practicable, but in any event within ninety (90) days after the
Company’s receipt of such written request, file and use its commercially reasonable efforts to effect such registration (including, without limitation, filing post-effective amendments, appropriate qualifications under applicable blue sky or
other state securities laws, and appropriate compliance with the Securities Act) and to permit or facilitate the sale and 

  
 5 

 
distribution of all or such portion of such Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any Holder or Holders
joining in such request as are specified in a written request received by the Company within thirty (30) days after such written notice from the Company is mailed or delivered. 

(b) Limitations on Requested Registration. The Company shall not be obligated to effect, or to take any action to effect,
any such registration pursuant to this Section 2.1: 
 (i) Prior to the earlier of (A) the four
(4) year anniversary of the date of this Agreement or (B) six (6) months following the effective date of the first registration statement filed by the Company covering an underwritten offering of any of its securities to the general public
(or the subsequent date on which all market stand-off agreements applicable to the offering have terminated, not to exceed an additional thirty-four (34) days); 

(ii) If the Company has not yet offered securities pursuant to a registration statement and the Initiating Holders propose to sell less than
20% of the Registrable Securities held by such Initiating Holders unless such lesser number of Registrable Securities proposed to be sold by the Initiating Holders is expected to result in aggregate proceeds of at least $20,000,000 (or if after the
Initial Public Offering, Registrable Securities with an anticipated aggregate offering price of at least $2,000,000); 
 (iii) In any
particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting such registration, qualification, or compliance, unless the Company is already subject to service in such jurisdiction and
except as may be required by the Securities Act; 
 (iv) After the Company has initiated two (2) such registrations pursuant to this
Section 2.1 (counting for these purposes only (x) registrations which have been declared or ordered effective and pursuant to which securities have been sold, and (y) Withdrawn Registrations); 

(v) During the period that is thirty (30) days prior to the Company’s good faith estimate of the date of filing of, and ending on a
date ninety (90) days (or one hundred eighty (180) days, in the case of an Initial Public Offering) after the effective date of a Company-initiated registration (or ending on the subsequent date on which all market stand-off agreements applicable to the offering have terminated, not to exceed an additional thirty-four (34) days); provided that the Company is actively employing in good faith commercially reasonable efforts
to cause such registration statement to become effective; or 
 (vi) If the Initiating Holders propose to dispose of shares of Registrable
Securities that may be registered on Form S-3 pursuant to a request made under Section 2.3 hereof. 

(c) Deferral. If (i) in the good faith judgment of the Board, the filing of a registration statement covering the
Registrable Securities would (x) materially interfere with a 

  
 6 

 
significant acquisition, corporate reorganization, or other similar transaction involving the Company; (y) require premature disclosure of material information that the Company has a bona
fide business purpose for preserving as confidential; or (z) render the Company unable to comply with requirements under the Securities Act or Exchange Act, and the Board concludes, as a result, that it is in the best interests of the Company
to defer the filing of such registration statement at such time, and (ii) the Company shall furnish to such Holders a certificate signed by the President (or other comparable senior executive officer) of the Company stating that in the good
faith judgment of the Board, it would be materially detrimental to the Company for such registration statement to be filed in the near future and that it is, therefore, in the best interests of the Company to defer the filing of such registration
statement, then (in addition to the limitations set forth in Section 2.1(b)(v) above) the Company shall have the right to defer such filing for a period of not more than one hundred (100) days after receipt of the
request of the Initiating Holders, and, provided further, that the Company shall not defer its obligation in this manner more than two (2) times in any twelve-month period. 

(d) Other Shares. The registration statement filed pursuant to the request of the Initiating Holders may, subject to the
provisions of Section 2.1(e), include Other Shares, and may include securities of the Company being sold for the account of the Company. 

(e) Underwriting. If the Initiating Holders intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as part of their request made pursuant to this Section 2.1 and the Company shall include such information in the written notice given pursuant to
Section 2.1(a)(i). In such event, the right of any Holder to include all or any portion of its Registrable Securities in a registration pursuant to this Section 2.1 shall be conditioned upon such
Holder’s participation in a underwriting. In such case, if the Company shall request inclusion in any registration pursuant to Section 2.1 of securities being sold for its own account, or if other persons shall request
inclusion in any registration pursuant to Section 2.1, the Initiating Holders shall, on behalf of all Holders, offer to include such securities in the underwriting and such offer shall be conditioned upon the participation
of the Company or such other persons in such underwriting and the inclusion of the Company’s and such person’s other securities of the Company and their acceptance of the further applicable provisions of this
Section 2 (including Section 2.10). The Company shall (together with all Holders and other persons proposing to distribute their securities through such underwriting) enter into an underwriting
agreement in customary form with the representative of the underwriter or underwriters selected for such underwriting by the Initiating Holders holding in the aggregate of a majority of the Registrable Securities held by the Initiating Holders,
which underwriters are reasonably acceptable to the Company; provided, however, that the liability of each holder as set forth therein shall be several and not joint. 

Notwithstanding any other provision of this Section 2.1, if the underwriters advise the Initiating Holders in
writing that marketing factors require a limitation on the number of shares to be underwritten, the number of Registrable Securities and Other Shares that may be so included shall be allocated as follows: (i) first, among all Holders requesting
to include Registrable Securities in such registration statement based on the pro rata percentage of Registrable Securities held by such Holders, assuming conversion (provided that if’, by operation of this clause (i), the number of Registrable
Securities to be so included is reduced to less than 

  
 7 

 
50% of the aggregate number of Registrable Securities so requested by all Holders to be included, then the Holders in the aggregate of a majority of the Registrable Securities; may withdraw the
request for such registration and, in such a case, (A) such registration shall not be counted as a registration “initiated” by the Company for purposes of Section 2.1(b)(iv) or “effected” by the
Company for purposes of Section 2.3(b)(iii) and (B) the Company shall bear the Registration Expenses of such registration notwithstanding any provision of Section 2.4 to the contrary); (ii)
second, among all Other Selling Stockholders requesting to include Other Shares in such registration statement based on the pro rata percentage of Other Shares held by such Other Selling Stockholders, assuming conversion; and (iii) third, to
the Company, which the Company may allocate, at its discretion, for its own account, or for the account of other stockholders or employees of the Company. If a person who has requested inclusion in such registration as provided above does not agree
to the terms of any such underwriting, such person shall be excluded therefrom by written notice from the Company, the underwriter or, if applicable, the Initiating Holders. The securities so excluded shall also be withdrawn from registration. Any
Registrable Securities or other securities excluded or withdrawn from such underwriting shall also be withdrawn from such registration. If shares are so withdrawn from the registration and if the number of shares to be included in such registration
was previously reduced as a result of marketing factors pursuant to this Section 2.1(e), then the Company shall then offer to all Holders and Other Selling Stockholders who have retained rights to include securities in the
registration the right to include additional Registrable Securities or Other Shares in the registration in an aggregate amount equal to the number of shares so withdrawn, with such shares to be allocated among such Holders and Other Selling
Stockholders requesting additional inclusion, as set forth above. 
 2.2 Company Registration. 

(a) Registration. If the Company shall determine to register any of its securities either for its own account or the
account of a security holder or holders, other than a registration pursuant to Section 2.1 or Section 2.3, a registration relating solely to employee benefit plans, a registration relating to the
offer and sale of debt securities only, or a registration relating to a corporate reorganization or other Rule 145 transaction, the Company will: 

(i) promptly give written notice of the proposed registration to all Holders; and 

(ii) use its commercially reasonable efforts include in such registration (and any related qualification under blue sky laws or other
compliance), except as set forth in Section 2.2(b) below, and in any underwriting involved therein, all of such Registrable Securities as are specified in a written request or requests made by any Holder or Holders received
by the Company within ten (10) days after such written notice from the Company is mailed or delivered. Such written request may specify all or a part of a Holder’s Registrable Securities. 

(b) Underwriting. If the registration of which the Company gives notice is for a registered public offering involving an
underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to Section 2.2(a)(î). In such event, the right of any Holder to registration pursuant to this
Section 2.2 shall be conditioned upon such 

  
 8 

 
Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to
distribute their securities through such underwriting shall (together with the Company, the Other Selling Stockholders and other holders of securities of the Company with registration rights to participate therein distributing their securities
through such underwriting) enter into an underwriting agreement in customary form with the representative of the underwriter or underwriters selected by the Company. 

Notwithstanding any other provision of this Section 2.2, if the underwriters advise the Company in writing that
marketing factors require a limitation on the number of shares to be underwritten, the underwriters may (subject to the limitations set forth below) limit the number of Registrable Securities to be included in, the registration and underwriting, the
Company shall so advise all holders of securities requesting registration, and the number of shares of securities that are entitled to be included in the registration and underwriting shall be allocated, as follows: (i) first, to the Company
for securities being sold for its own account; (ii) second, to the Holders requesting to include Registrable Securities in such registration statement based on the pro rata percentage of Registrable Securities held by such Holders, assuming
conversion; and (iii) third, to the Other Selling Stockholders requesting to include Other Shares in such registration statement based on the pro rata percentage of Other Shares held by such Other Selling Stockholders, assuming conversion.
Notwithstanding the foregoing, no such reduction shall reduce the value of the Registrable Securities of the Holders included in such registration below twenty-five percent (25%) of the total value of securities included in such registration, unless
such offering is an Initial Public Offering and such registration does not include shares of any Other Selling Stockholder (excluding shares registered for the account of the Company), in which event any or all of the Registrable Securities of such
Holders may be excluded. 
 If a person who has requested inclusion in such registration as provided above does not agree to the terms of
any such underwriting, such person shall also be excluded therefrom by written notice from the Company or the underwriter. The Registrable Securities or other securities so excluded shall also be withdrawn from such registration. Any Registrable
Securities or other securities excluded or withdrawn from such underwriting shall be withdrawn from such registration. 
 (c)
Right to Terminate Registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.2 prior to the effectiveness of such registration whether or not
any Holder has elected to include securities in such registration. 
 2.3 Registration on Form
S-3. 
 (a) Request for Form S-3
Registration. After its Initial Public Offering, the Company shall use its commercially reasonable efforts to qualify for registration on Form S-3 or any comparable or successor form or forms. After
the Company has qualified for the use of Form S-3, in addition to the rights contained in the foregoing provisions of this Section 2 and subject to the conditions set forth in this
Section 2.3, if the Company shall receive from a Holder or Holders of Registrable Securities a written request that the Company effect any registration on 

  
 9 

 
Form S-3 or any similar short form registration statement with respect to all or part of the Registrable Securities (such request shall state the number of
shares of Registrable Securities to be disposed of and the intended methods of disposition of such shares by such Holder or Holders), the Company will take all such action with respect to such Registrable Securities as required by Sections
2.1(a)(î) and 2.1(a)(ii). 
 (b) Limitations on Form S-3 Registration.
The Company shall not be obligated to effect, or take any action to effect, any such registration pursuant to this Section 2.3: 

(i) In the circumstances described in any of Sections 2.1(b)(i), 2.1(b)(iii) or 2.1(b)(v); 

(ii) If the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to
sell Registrable Securities and such other securities (if any) on Form S-3 at an aggregate price to the public of less than $2,000,000; or 

(iii) If, in a given twelve-month period, the Company has effected two (2) such registrations in such period. 

(c) Deferral. The provisions of Section 2.1(c) shall apply to any registration pursuant to this
Section 2.3. 
 (d) Underwriting. If the Holders of Registrable Securities requesting
registration under this Section 2.3 intend to distribute the Registrable Securities covered by their request by means of an underwriting, the provisions of Section 2.1(e) shall apply to such
registration. Notwithstanding anything contained herein to the contrary, registrations effected pursuant to this Section 2.3 shall not be counted as requests for registration or registrations effected pursuant to
Section 2.1. 
 2.4 Expenses of Registration. All Registration Expenses incurred in
connection with registrations pursuant to Sections 2.1, 2.2 and 2.3 hereof shall be borne by the Company; provided, however, that, subject to Section 2.1(e), the Company shall not be
required to pay for any Registration Expenses of any registration proceeding begun pursuant to Sections 2.1 and 2.3 if the registration request is subsequently withdrawn at the request of the Holders in the aggregate of a majority of
the Registrable Securities; or because a sufficient number of Holders shall have withdrawn so that the minimum offering conditions set forth in Section 2.1 and 2.3 are no longer satisfied (in which case all
participating Holders shall bear such expenses pro rata among each other based on the number of Registrable Securities requested to be so registered), unless the Holders in the aggregate of a majority of the Registrable Securities agree to forfeit
their right to a demand registration pursuant to Section 2.1; provided, however, in the event that a withdrawal by the Holders is based upon material adverse information relating to the Company that is
different from the information known or available (upon request from the Company or otherwise) to the Holders requesting registration at the time of their request for registration under Sections 2.1 or 2.3, such registration shall not
be treated as a counted registration for purposes of Sections 2.1 or 2.3 hereof, and the Company shall bear the Registration Expenses for such 

  
 10 

 
registration. All Selling Expenses relating to securities registered on behalf of the Holders shall be borne by the holders of securities included in such registration pro rata among each other
on the basis of the number of Registrable Securities so registered. 
 2.5 Registration Procedures. In the case of each
registration effected by the Company pursuant to Section 2, the Company will keep each Holder advised in writing as to the initiation of each registration and as to the completion thereof. At its expense, the Company will
use its commercially reasonable efforts to: 
 (a) Keep such registration effective for a period of ending on the earlier of the date
which is sixty (60) days from the effective date of the registration statement or such time as the Holder or Holders have completed the distribution described in the registration statement relating thereto; 

(b) To the extent the Company is a well-known seasoned issuer (as defined in Rule 405 under the Securities Act) (a
“WKSI”) at the time any request for registration is submitted to the Company in accordance with Section 2.3, (i) if so requested, file an automatic shelf registration statement (as defined in Rule
405 under the Securities Act) (an “automatic shelf registration statement”) to effect such registration, and (ii) remain a WKSI (and not become an ineligible issuer (as defined in Rule 405 under the Securities Act))
during the period during which such automatic shelf registration statement is required to remain effective in accordance with this Agreement; 

(c) Prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus used in
connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement for the period set forth in subsection
(a) above; 
 (d) Furnish such number of prospectuses, including any preliminary prospectuses, and other documents incident
thereto, including any amendment of or supplement to the prospectus, as a Holder from time to time may reasonably request; 
 (e)
Register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdiction as shall be reasonably requested by the Holders; provided, that the Company shall not be required in
connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions; 

(f) Notify each seller of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto
is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a
material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing, and following such notification promptly prepare and furnish to such seller a
reasonable number of copies of a 

  
 11 

 
supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such shares, such prospectus shall not include an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing; 

(g) If at any time when the Company is required to re-evaluate its WKSI status for purposes of
an automatic shelf registration statement used to effect a request for registration in accordance with Section 2.3, (i) the Company determines that it is not a WKSI, (ii) the registration statement is required to be kept effective in
accordance with this Agreement, and (iii) the registration rights of the applicable Holders have not terminated, reasonably promptly amend the registration statement onto a form the Company is then eligible to use or file a new registration
statement on such form, and keep such registration statement effective in accordance with the requirements otherwise applicable under this Agreement; 

(h) If (i) a registration made pursuant to a shelf registration statement is required to be kept effective in accordance with this
Agreement after the third anniversary of the initial effective date of the shelf registration statement and (ii) the registration rights of the applicable Holders have not terminated, file a new registration statement with respect to any unsold
Registrable Securities subject to the original request for registration prior to the end of the three year period after the initial effective date of the shelf registration statement, and keep such registration statement effective in accordance with
the requirements otherwise applicable under this Agreement; 
 (i) Furnish, on the date that such Registrable Securities are
delivered to the underwriters for sale, if such securities are being sold through underwriters, (i) an opinion, dated as of such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is
customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and (ii) a “comfort” letter dated as of such date, from the independent certified public accountants of the Company, in form
and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters; 

(j) Provide a transfer agent and registrar for all Registrable Securities registered pursuant to such registration statement and a
CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 
 (k)
Otherwise comply with all applicable rules and regulations of the Commission, and make available to its security holders, as soon as reasonably practicable, an earnings statement covering the period of at least twelve months, but not more than
eighteen months, beginning with the first month after the effective date of the Registration Statement, which earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act; 

(l) Cause all such Registrable Securities registered pursuant hereunder to be listed on each securities exchange on which similar
securities issued by the Company are then listed; provided that in the case of the Initial Public Offering, the Registrable Securities shall be listed on a national securities exchange; and 

  
 12 

 (m) In connection with any underwritten offering pursuant to a registration statement
filed pursuant to Section 2.1 hereof, enter into an underwriting agreement in form reasonably necessary to effect the offer and sale of Common Stock, provided such underwriting agreement contains reasonable and
customary provisions, and provided further, that each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. 

2.6 Indemnification. 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, each of its officers, directors and
partners, legal counsel and accountants and each person controlling such Holder within the meaning of Section 15 of the Securities Act, with respect to which registration, qualification or compliance has been effected pursuant to this
Section 2, and each underwriter, if any, and each person who controls within the meaning of Section 15 of the Securities Act any underwriter, against all expenses, claims, losses, damages and liabilities (or actions,
proceedings or settlements in respect thereof) arising out of or based on: (i) any untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any registration statement, prospectus, offering
circular, issuer free writing prospectus (as defined in Rule 433 of the Securities Act), issuer information (as defined in Rule 433 of the Securities Act) filed or required to be filed pursuant to Rule 433(d) under the Securities Act or any other
document incident to any such registration or related qualification or compliance, (ii) any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not
misleading, or (iii) any violation (or alleged violation) by the Company of the Securities Act, any state securities laws or any rule or regulation thereunder applicable to the Company and relating to action or inaction required of the Company
in connection with any offering covered by such registration, qualification or compliance, and the Company will reimburse each such Holder, each of its officers, directors, partners, legal counsel and accountants and each person controlling such
Holder, each such underwriter and each person who controls any such underwriter, for any legal and any other expenses reasonably incurred in connection with investigating and defending or settling any such claim, loss, damage, liability or action;
provided that the Company will not be liable in any such case to the extent that any such claim, loss, damage, liability, or action arises out of or is based on any untrue statement or omission based upon written information furnished to the
Company by such Holder, any of such Holder’s officers, directors, partners, legal counsel or accountants, any person controlling such Holder, such underwriter or any person who controls any such underwriter, and stated to be specifically for
use therein except to the extent such information was corrected in a subsequent writing prior to or concurrently with the sale of Registrable Securities to the person or entity asserting the claim; and provided, further that, the
indemnity agreement contained in this Section 2.6(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company
(which consent shall not be unreasonably withheld). 

  
 13 

 (b) To the extent permitted by law, each Holder will, if Registrable Securities held
by such Holder are included in the securities as to which such registration, qualification or compliance is being effected, indemnify and hold harmless the Company, each of its directors, officers, partners, legal counsel and accountants and each
underwriter, if any, of the Company’s securities covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of Section 15 of the Securities Act, each other such Holder, and each of
their officers, directors and partners, and each person controlling each other such Holder, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based on (in each case only to the extent that such
claims, losses, damages and liabilities arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such
registration except to the extent such information was corrected in a subsequent writing prior to or concurrently with the sale of Registrable Securities to the person or entity asserting the claim): (i) any untrue statement (or alleged untrue
statement) of a material fact contained or incorporated by reference in any prospectus, offering circular or other document (including any related registration statement, notification, or the like) incident to any such registration, qualification or
compliance, or (ii) any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the Company and such Holders, directors,
officers, partners, legal counsel and accountants, persons, underwriters, or control persons for any legal or any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action, in
each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular or other document in reliance upon and
in conformity with written information furnished to the Company by such Holder and stated to be specifically for use therein; provided, however, that the obligations of such Holder hereunder shall not apply to amounts paid in
settlement of any such claims, losses, damages or liabilities (or actions in respect thereof) if such settlement is effected without the consent of such Holder (which consent shall not be unreasonably withheld); and provided that in no event
shall any indemnity under this Section 2.6(b) exceed the net proceeds from the offering received by such Holder, except in the case of fraud or willful misconduct by such Holder. 

(c) Each party entitled to indemnification under this Section 2.6 (the “Indemnified Party”) shall give
notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying
Party to assume the defense of such claim or any litigation resulting therefrom; provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or any litigation resulting therefrom, shall be approved by the
Indemnified Party (whose approval shall not be unreasonably withheld), and the Indemnified Party may participate in such defense at such party’s expense; and provided further that the failure of any Indemnified Party to give notice as
provided herein shall not relieve the Indemnifying Party of its obligations under this Section 2.6, to the extent such failure is not prejudicial. No Indemnifying Party, in the defense of any such claim or litigation,
shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a
release from all liability in 

  
 14 

 
respect to such claim or litigation. Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably request in writing and
as shall be reasonably required in connection with defense of such claim and litigation resulting therefrom. 
 (d) If the
indemnification provided for in this Section 2.6 is held by a court of competent jurisdiction to be unavailable to an Indemnified Party with respect to any loss, liability, claim, damage, or expense referred to herein, then
the Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage, or expense in such proportion as is
appropriate to reflect the relative fault of the Indemnifying Party on the one hand and of the Indemnified Party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as
any other relevant equitable considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the
omission to state a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or
omission. No person or entity will be required under this Section 2.6(d) to contribute any amount in excess of the net proceeds from the offering received by such person or entity, except in the case of fraud or willful
misconduct by such person or entity. No person or entity guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person or entity who was not guilty of such
fraudulent misrepresentation. 
 (e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and
contribution contained in the underwriting agreement entered into by the Investors in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control;
provided that the failure of the underwriting agreement to provide for or address a matter provided for or addressed in the foregoing provisions shall not be a conflict with the foregoing provisions and, in such event, the foregoing
provisions shall control. 
 2.7 Information by Holder. Each Holder of Registrable Securities shall furnish to the
Company such information regarding such Holder and the distribution proposed by such Holder as the Company may reasonably request in writing and as shall be reasonably required in connection with any registration, qualification, or compliance
referred to in this Section 2. 
 2.8 Restrictions on Transfer. 

(a) The holder of each certificate representing Registrable Securities by acceptance thereof agrees to comply in all respects with the
provisions of this Section 2.8. Each Holder agrees not to make any sale, assignment, transfer, pledge or other disposition of all or any portion of the Restricted Securities, or any beneficial interest therein, unless and until: 

  
 15 

 (i) There is then in effect a registration statement under the Securities Act covering such
proposed disposition and the disposition is made in accordance with the registration statement; or 
 (ii) (x) the Holder shall have given
prior written notice to the Company of the Holder’s intention to make such disposition and shall have furnished the Company with a detailed description of the manner and circumstances of the proposed disposition, (y) if such transfer is
prior to the Company’s Initial Public Offering, the transferee thereof shall have agreed in writing for the benefit of the Company to take and hold such Restricted Securities subject to, and to be bound by, the terms and conditions set forth in
this Agreement, including, without limitation, this Section 2.8 and Section 2.10, and (z) if reasonably requested by the Company, the Holder shall have furnished the Company, at its expense,
with (1) an opinion of counsel reasonably satisfactory to the Company to the effect that such disposition will not require registration of such Restricted Securities under the Securities Act or (2) a “no action” letter from the
Commission to the effect that the transfer of such securities without registration will not result in a recommendation by the staff of the Commission that action be taken with respect thereto, whereupon the holder of such Restricted Securities shall
be entitled to transfer such Restricted Securities in accordance with the terms of the notice delivered by the Holder to the Company. 

(b) Notwithstanding the provisions of Section 2.8(a), no such registration statement, opinion of counsel or
“no action” letter shall be required for (i) a transfer not involving a change in beneficial ownership, (ii) a transfer under Rule 144, except in unusual circumstances, or (iii) transactions involving the transfer of
Restricted Securities by any Holder to (x) a parent, subsidiary or other Affiliate of the Holder; (y) any of the Holder’s partners, members or other equity owners, or retired partners, retired members or other equity owners, or to the
estate of any of the Holder’s partners, members or other equity owners or retired partners, retired members or other equity owners; or (z) any venture capital fund that is controlled by or under common control with one or more general
partners or managing members of, or shares the same management company with, the Holder; provided, in each case, that the Holder shall give written notice to the Company of the Holder’s intention to effect such disposition and shall have
furnished the Company with a detailed description of the manner and circumstances of the proposed disposition and, if such transfer is prior to the Company’s Initial Public Offering, the transferee thereof shall have agreed in writing for the
benefit of the Company to take and hold such Restricted Securities subject to, and to be bound by, the terms and conditions set forth in this Agreement, including, without limitation, this Section 2.8 and
Section 2.10. 
 (c) Each certificate representing Registrable Securities shall (unless otherwise permitted
by the provisions of this Agreement) be stamped or otherwise imprinted with a legend substantially similar to the following (in addition to any legend required under applicable state securities laws): 

THE OFFER AND SALE OF THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE 

  
 16 

 
SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO REGISTRATION OR AN
EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE
SECURITIES LAWS. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, INCLUDING A LOCK-UP PERIOD IN THE EVENT OF A PUBLIC OFFERING, AS SET FORTH IN AN INVESTORS’ RIGHTS AGREEMENT AMONG THE COMPANY AND THE ORIGINAL HOLDERS OF THESE SHARES, COPIES OF WHICH MAY BE OBTAINED AT THE PRINCIPAL
OFFICE OF THE COMPANY. 
 The Holders consent to the Company making a notation on its records and giving instructions to any transfer agent
of the Restricted Securities in order to implement the restrictions on transfer established in this Section 2.8. 

(d) The first legend referring to federal and state securities laws identified in Section 2.8(b) hereof
stamped on a certificate evidencing the Restricted Securities and the stock transfer instructions and record notations with respect to such Restricted Securities shall be removed and the Company shall issue a certificate without such legend to the
holder of such Restricted Securities if (i) such securities are registered under the Securities Act, or (ii) such holder provides the Company with an opinion of counsel reasonably acceptable to the Company to the effect that a sale or
transfer of the securities may be made without registration or qualification. 
 (e) Notwithstanding anything to the contrary in this
Agreement, (i) any or all of an Investor’s rights hereunder may be exercised by, and any or all of an Investor’s obligations hereunder may be discharged by, one or more Affiliates of such Investor designated by such Investor and
(ii) more specifically, (x) an Investor may cause any shares of capital stock of the Company (or any securities directly or indirectly exercisable for, or convertible into or exchangeable for, such shares) required or permitted to be
purchased or otherwise acquired hereunder by such Investor to be so purchased or acquired, in lieu of such Investor, by an Affiliate of such Investor (and such Affiliate shall then become an “Investor” hereunder), and (y) any Investor
holding securities directly or indirectly exercisable for, or convertible into or exchangeable for, shares of capital stock of the Company shall have the right to have any such shares (or other securities) issuable upon the conversion, exercise or
exchange of the securities held by such Investor issued in the name of one or more Affiliates of such Investor designated by such Investor (and each such Affiliate shall then become an “Investor” hereunder). 

  
 17 

 2.9 Rule 144 Reporting. With a view to making available the benefits of
certain rules and regulations of the Commission that may permit the sale of the Restricted Securities to the public without registration, the Company agrees to use its commercially reasonable efforts to: 

(a) Make and keep adequate current public information with respect to the Company available in accordance with Rule 144 under the
Securities Act, at all times from and after ninety (90) days following the effective date of the first registration under the Securities Act filed by the Company for an offering of its securities to the general public; 

(b) File with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and
the Exchange Act at any time after it has become subject to such reporting requirements; and 
 (c) So long as a Holder owns any
Restricted Securities, furnish to the Holder forthwith upon written request a written statement by the Company as to its compliance with the reporting requirements of Rule 144 (at any time from and after ninety (90) days following the effective
date of the first registration statement filed by the Company for an offering of its securities to the general public), and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), a copy
of the most recent annual or quarterly report of the Company, and such other reports and documents so filed as a Holder may reasonably request in availing itself of any rule or regulation of the Commission allowing a Holder to sell any such
securities without registration. 
 2.10 Market Stand-Off Agreement. Each
Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the Initial Public Offering and ending on the date specified by the
Company and the managing underwriter (such period not to exceed one hundred eighty (180) days, or such other period as may be reasonably requested by the underwriters to accommodate regulatory restrictions on (i) the publication or other
distribution of research reports and (ii) analyst recommendations and opinions) (a) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or
warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock held immediately prior to the effectiveness of the
Initial Public Offering, or (b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause
(a) or (b) above is to be settled by delivery of Common Stock or other securities, in cash or otherwise. The foregoing provisions of this Section 2.10 shall apply only to the Initial Public Offering, shall not apply to
the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall only be applicable to the Holders if all officers, directors and greater than one percent (1%) stockholders of the Company enter into similar agreements. The
underwriters in connection with the Initial Public Offering are intended third-party beneficiaries of this Section 2.10 and shall have the right, power and authority to enforce the provisions hereof as though they were a
party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in the Initial Public Offering that are consistent with this Section 2.10 or that are necessary to give
further effect thereto. Any 

  
 18 

 
discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Company stockholders that are subject to
such agreements, based on the number of shares subject to such agreements. For the avoidance of doubt, this Section 2.10 shall not apply to shares of Common Stock acquired in the Initial Public Offering or in the open
market following the Initial Public Offering. 
 In order to enforce the foregoing covenant, the Company may impose stop-transfer
instructions with respect to the Registrable Securities of each Holder (and the shares or securities of every other person subject to the foregoing restriction) until the end of such period. 

2.11 Delay of Registration. No Holder shall have any right to take any action to restrain, enjoin, or otherwise delay any
registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.12 Transfer or Assignment of Registration Rights. The rights to cause the Company to register securities granted to a
Holder by the Company under this Section 2 may be transferred or assigned by a Holder only to a transferee or assignee of not less than twenty percent (20%) of the Registrable Securities (as presently constituted and
subject to subsequent adjustments stock splits, stock dividends, combinations, subdivisions, recapitalizations or the like) then held by such Holder; provided that (i) such transfer or assignment of Registrable Securities is effected in
accordance with the terms of Section 2.8 hereof and applicable securities laws, (ii) the Company is given written notice prior to said transfer or assignment, stating the name and address of the transferee or assignee
and identifying the securities with respect to which such registration rights are intended to be transferred or assigned and (iii) the transferee or assignee of such rights assumes in writing the obligations of such Holder under this Agreement,
including without limitation the obligations set forth in Section 2.10. The foregoing twenty percent (20%) threshold shall not be applicable to any transfers among Affiliates. 

2.13 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not,
without the prior written consent of the Holders in the aggregate of a majority of the Registrable Securities, enter into any agreement with any holder or prospective holder of any securities of the Company giving such holder or prospective holder
any registration rights the terms of which are senior to or on parity with the registration rights granted to the Holders hereunder. 

2.14 Termination of Registration Rights. The right of any Holder to request registration or inclusion in any registration
pursuant to Sections 2.1, 2.2 or 2.3 above shall terminate on the earlier of: (i) following the closing of the Company’s first registered public offering of Common Stock, with respect to any Holder who then holds an
amount of Registrable Securities that is equal to less than one percent (1%) of the outstanding securities of the Company and may sell all such Registrable Securities under Rule 144 during any ninety (90) day period, and (ii) four (4)
years after the closing of a Qualified Public Offering. 

  
 19 

 3. Certain Covenants. 

The Company hereby covenants and agrees, as follows: 

3.1 Basic Financial Information and Inspection Rights. 

(a) Basic Financial Information. As long as at least twenty percent (20%) of the shares of Preferred Stock originally
issued remain outstanding, the Company will deliver to each Major Investor: 
 (i) as soon as practicable after the end of each fiscal year
of the Company, and in any event within 150 days after the end of each fiscal year of the Company a consolidated balance sheet of the Company and its subsidiaries, if any, as at the end of such fiscal year, and consolidated statements of income and
cash flows of the Company and its subsidiaries, if any, for such year, prepared in accordance with U.S. generally accepted accounting principles consistently applied, and audited and certified by independent public accountants of recognized national
standing selected by the Company, which audit may be waived by a vote of the Preferred Majority, in which case the Company shall deliver such unaudited statements within 60 days after the end of such fiscal year; 

(ii) as soon as practicable after the end of the first, second and third quarterly accounting periods in each fiscal year of the Company, and
in any event within 45 days after the end of the first, second, and third quarterly accounting periods in each fiscal year of the Company, an unaudited consolidated balance sheet of the Company and its subsidiaries, if any, as of the end of each
such quarterly period, and unaudited consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such period, prepared in accordance with U.S. generally accepted accounting principles consistently applied,
subject to changes resulting from normal year-end audit adjustments and such financial statements may not contain accompanying notes; 

(iii) as soon as practicable after the each month, and in any event within 30 days after the end of each such month, an unaudited
consolidated balance sheet of the Company and its subsidiaries, if any, as of the end of each such monthly period, and unaudited consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such period, prepared
in accordance with U.S. generally accepted accounting principles consistently applied, subject to changes resulting from normal year-end audit adjustments and such financial statements may not contain
accompanying notes, along with a comparison of such results to the Company’s operating plan; 
 (iv) at least 30 days prior to the
beginning of each of the Company’s fiscal years an annual operating plan for such fiscal year (and as soon as available, any subsequent material revisions thereto); 

(v) as soon as practicable after the end of each fiscal year, and in any event within 30 days thereafter, a report setting forth in detail
all equity and debt holders of the Company as of the end of such year; 

  
 20 

 (vi) a capitalization table promptly upon the request of a Major Investor, but no more
frequently than once per calendar quarter; and 
 (vii) such other information relating to the financial condition or business of the
Company as any Major Investor may, from time to time, reasonably request related to monitoring its investment in the Company; provided, however, that the Company shall not be obligated under this Subsection 3.1(a)
to provide a complete set of materials prepared by or on behalf of the Company for the purpose of distribution to the Board or any information: (i) that the Company reasonably determines in good faith to be a trade secret or confidential
information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company, and is not a trade secret described in the next clause); (ii) that the Company reasonably determines in good faith to be a technology or
scientific trade secret; or (iii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

Notwithstanding anything else set forth herein, the Company shall deliver to each Investor that is not a Major Investor and continues to hold
at least fifty percent (50%) of the shares of Preferred Stock originally purchased by such Investor the annual financial reports set forth in Section 3.1(a)(i) above and the quarterly financial reports set forth in
Section 3.1(a)(ii) above at the same time the Company delivers such reports to the Major Investors. 

Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information set forth in this
Section 3.1 during the period starting with the date 30 days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to
such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause
such registration statement to become effective. 
 (b) Inspection Rights. The Company shall permit each Major Investor
to visit and inspect any of the properties of the Company or any of its subsidiaries during normal business hours or at such other reasonable times as may be requested, and to discuss the affairs, finances and accounts of the Company or any of its
subsidiaries with its officers, and to review such information as is reasonably requested all at such reasonable times and as often as may be reasonably requested; provided, however, that the Company shall not be obligated under this
Section 3.1(b) with respect to a competitor of the Company (as determined by the Board in good faith) or with respect to information which the Board determines in good faith is highly confidential or attorney-client
privileged and should not, therefore, be disclosed; provided, however that no Major Investor shall be deemed a competitor solely as a result of holding less than twenty percent (20%) of the outstanding equity of an entity or as a result of
maintaining a right to designate any members of the board of directors of a competitor. Each Major Investor may exercise its rights under this Section 3.1(b) only for purposes reasonably related to its interests as a
stockholder of the Company. The rights granted pursuant to this Section 3.1(b) may not be assigned or otherwise conveyed to any Holder or by any subsequent transferee of any such rights without the prior written consent of
the Company; provided, however, that a Major Investor shall be permitted to transfer rights granted pursuant to this Section 3.1(b) to Affiliates of such Major Investor. 

  
 21 

 3.2 Confidentiality. Each Holder agrees that such Holder will keep
confidential and will not use for any purpose (other than to monitor its investment) or disclose or divulge any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s
intention to file a registration statement and the contents of any financial statements received), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this
Section 3.2 by such Holder or as a result of a breach by a third party of any obligation of confidentiality such third party may have to the Company of which such Holder is aware), (b) is or has been independently developed
or conceived by Holder without use of or reference to the Company’s confidential information, or (c) is or has been made known or disclosed to the Holder by a third party without a breach of any obligation of confidentiality such third
party may have to the Company; provided, however, that a Holder may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with
monitoring its investment in the Company, provided such persons agree to hold such information confidentially as provided herein; (ii) to any prospective purchaser of any Registrable Securities from such Holder, if such prospective purchaser
agrees to be bound by the provisions of this Section 3.2; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Holder in the ordinary course of business, but only
on the condition that such Affiliate, partner, member, stockholder or wholly owned subsidiary of such Holder shall only use such confidential information in connection with monitoring such Holder’s investment in the Company and not for any
other purpose, and provided that such Holder informs such person or entity that such information is confidential and directs such person or entity to maintain confidential treatment of such information; or (iv) as may otherwise be required by
law, provided that the Holder promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 

3.3 Right to Conduct Activities. The Company hereby agrees and acknowledges that each of the Investors and their
respective Affiliates (each, a “Fund”) are investment funds or engage in corporate venture and other investment activities, and as such review the business plans and related proprietary information of many enterprises and
invest in numerous portfolio companies, may compete directly or indirectly with the Company’s business (as currently conducted or as currently propose to be conducted). The Company hereby agrees that, to the extent permitted by applicable law,
no Fund nor its partners, employees, Affiliates, advisors or affiliated investment funds shall be liable to the Company for any claim arising out of, or based upon, (i) the investment by such Fund (or its Affiliates) in any entity, or
activities of such Affiliates, that may be competitive to the Company or (ii) actions taken by any partner, officer, advisor, employee or other representative of such Fund (or its Affiliates) in his, her or its capacity as such to assist any
such competitive company whether or not such action was taken as a member of the board of directors of such competitive company or otherwise; provided, however, that nothing herein shall relieve any Fund from liability associated with use or
disclosure of the Company’s confidential information in breach of Section 3.2 above or associated with a breach of any other obligation of confidentiality owed to the Company, nor

  
 22 

 
liability associated with violating, breaching or misappropriating any proprietary right of the Company, nor shall relieve any director or officer of the Company from any liability associated
with his or her breach of a fiduciary duty. 
 3.4 FCPA. The Company covenants that it shall not (and shall not permit
any of its subsidiaries or Affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of
value to, directly or indirectly, to any third party, including any Non-U.S. Official (as (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the
“FCPA”)), in each case, in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further covenants that it shall (and shall cause each of its subsidiaries and
Affiliates to) cease all of its or their respective activities, as well as remediate any actions taken by the Company, its subsidiaries or affiliates, or any of their respective directors, officers, managers, employees, independent contractors,
representatives or agents in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and affiliates to) maintain
systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon
request, the Company agrees to provide responsive information and/or certifications concerning its compliance with applicable anti-corruption laws. The Company shall promptly notify each Fund if the Company becomes aware of any enforcement action
pursuant to such laws. The Company shall, and shall cause any direct or indirect subsidiary or entity controlled by it, whether now in existence or formed in the future, to comply with the FCPA. 

3.5 Termination of Covenants. The covenants set forth in Section 3.1 and
Section 3.4 shall terminate and be of no further force and effect after the earlier of: (a) the Initial Public Offering; and (b) the occurrence of a Liquidation Event, except that such covenants shall not
terminate upon the consummation of a sale of all or substantially all of the assets of the Company; provided, however, that this Agreement may be terminated after such sale of all or substantially all of the assets of the Company upon the consent of
the Preferred Majority. 
 4. Right of First Refusal. 

4.1 Grant of Rights. Subject to the provisions of Section 4.2 through
Section 4.5 below, the Company hereby grants to each Investor that continues to hold at least 35% of the shares of Series B Preferred Stock or Series C Preferred Stock such Investor originally purchased (including through
the conversion of convertible promissory notes) who is an “accredited investor” within the meaning of applicable securities laws and regulations (a “ROFR Holder”), the right of first refusal to purchase its Pro Rata
Amount (as defined below) of New Securities which the Company may, from time to time, propose to sell and issue after the date of this Agreement. A ROFR Holder’s “Pro Rata Amount”, for purposes of this right of first
refusal, is equal to the ratio of (a) the number of shares of Common Stock together with the number of shares of Preferred Stock (and warrants or other securities exercisable for Preferred Stock) calculated on an as exercised and as converted
to Common Stock basis held by such ROFR 

  
 23 

 
Holder, to (b) the total of all outstanding shares of Common Stock and Preferred Stock and all other shares of other convertible securities, rights, options or warrants then outstanding, on
an as exercised and as converted to Common Stock basis. 
 4.2 New Securities. As used herein, “New
Securities” shall mean any capital stock (including Common Stock and/or Preferred Stock) of the Company whether now authorized or not, and rights, convertible securities, options or warrants to purchase such capital stock, and
securities of any type whatsoever that are, or may become, exercisable or convertible into capital stock, including debt instruments convertible into capital stock; provided that the term “New Securities” does not include
(i) Exempted Securities, as defined in the Restated Certificate, (ii) any shares of Series C Preferred Stock issued pursuant to the Series C Purchase Agreement, or (iii) any shares of stock of the Company issued in the Initial Public
Offering. 
 4.3 Notice. In the event the Company proposes to undertake an issuance of New Securities, it shall give
each ROFR Holder written notice of its intention, describing the type of New Securities, and their price and the general terms upon which the Company proposes to issue the same. Each ROFR Holder shall have fifteen (15) days after any such
notice is mailed or delivered to agree to purchase such ROFR Holder’s Pro Rata Amount (or such lesser amount as desired) of such New Securities for the price and upon the terms specified in the notice by giving written notice to the Company and
stating therein the quantity of New Securities to be purchased, if any. 
 4.4 Election Period and Excess Securities.
In the event the foregoing right of first refusal is not exercised in full by all of the ROFR Holders within the fifteen (15) day period described in Section 4.3 above (the “Election Period”),
the Company shall promptly notify in writing the ROFR Holders who have elected to exercise their right of first refusal with respect to their full Pro Rata Amounts and shall offer such ROFR Holders the right to acquire such unsubscribed New
Securities. Each ROFR Holder shall have five (5) days after receipt of such notice to notify the Company of its election to purchase all or a portion thereof of its pro rata portion of the unsubscribed New Securities, indicate whether it
intends to purchase unsubscribed New Securities in excess of its pro rata share (“Excess Securities”) and, if so, the number of such unsubscribed New Securities it wishes to purchase. The Excess Securities, if any, shall be
allocated to participating ROFR Holders in a manner most consistent with the pro rata shares of such participating ROFR Holders as determined in good faith by the Board. If the ROFR Holders fail to exercise in full their rights of first refusal, the
Company shall have forty-five (45) days thereafter to sell or enter into an agreement (pursuant to which the sale of New Securities covered thereby shall be closed, if at all, within twenty (20) days from the date of said agreement) to
sell that portion of the New Securities with respect to which the ROFR Holders’ right of first refusal option set forth in this Section 4 was not exercised, at a price and upon terms no more favorable to the purchasers
thereof than specified in the Company’s notice to ROFR Holders delivered pursuant to Section 4.3. In the event the Company enters into an agreement to sell such New Securities within such forty-five (45) day
period following the Election Period, or sells such New Securities within such twenty (20) day period following the date of said agreement, the Company shall not thereafter issue or sell any New Securities, without first again offering such
securities to the ROFR Holders in the manner provided in this Section 4. 

  
 24 

 4.5 Waiver, Termination, Transfer. The rights of first refusal granted
under this Section 4, including notice with respect thereto, may be waived pursuant to Section 7.6 of this Agreement. Notwithstanding the foregoing, if any of the waiving ROFR Holders purchase New
Securities covered by the waiver (any such purchase of New Securities, a “Waiver Purchase”), then each ROFR Holder shall have the right to purchase up to the same percentage of its Pro Rata Amount of the New Securities
purchased by the waiving ROFR Holder who purchased the highest percentage of its respective Pro Rata Amount of the New Securities (such right, a “ROFR Revival Right”). The rights of first refusal granted under this
Section 4 shall terminate immediately prior to the earliest: of (i) an Initial Public Offering, (ii) the closing of a Liquidation Event, except that such covenants shall not terminate upon the consummation of a
sale of all or substantially all of the assets of the Company unless agreed to in writing by the Preferred Majority, (iii) as to any Investor at such time it, together with its Affiliates, is no longer a ROFR Holder. The rights of first refusal
of a ROFR Holder under this Section 4 may be transferred subject to the same restrictions as any transfer of registration rights pursuant to Section 2.12. Notwithstanding anything else set forth
above, a ROFR Holder shall be permitted to transfer rights granted pursuant to this Section 4 in any amount to its Affiliates. 

5. Other Company Covenants. 

5.1 Employee Agreements. The Company shall require (i) all employees and consultants to execute and deliver a
nondisclosure and proprietary rights assignment agreement (in the case of employees, in substantially the form approved by the Board) and (ii) each executive-level employee (including, division director and vice president-level positions) as
well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Proprietary Rights (as defined in the Series C Purchase Agreement) to enter into a one (1) year noncompetition and nonsolicitation
agreement, substantially in the form approved by the Board (to the extent permitted under applicable law). In addition, the Company shall not materially amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the
above-referenced agreements or any restricted stock agreement between the Company and any employee, if such amendment would cause it to be inconsistent with this Section 5.1 without the consent of the Board, including the
consent of a majority of the Preferred Directors. 
 5.2 Equity Agreements. Unless otherwise approved by the Board,
including the consent of a majority of the Preferred Directors, all employees of the Company who purchase, or receive options to purchase, shares of Common Stock following the date hereof shall be required to execute stock purchase or option
agreements providing for: (a) vesting of shares over a four (4) year period with the first twenty five percent (25%) of such shares vesting following twelve (12) months of continued employment or services, and the remaining shares
vesting in equal monthly installments over the following thirty six (36) months thereafter; and (b) a vesting commencement date no earlier than such employee’s first date of employment with the Company. Without the prior approval by
the Board, including a majority of the Preferred Directors, the Company shall not amend, modify, terminate, waive or otherwise alter, in whole or in part, any stock purchase, stock restriction or option agreement with any existing employee or
service provider if such amendment would cause it to be inconsistent with this Section 5.2. 

  
 25 

 5.3 Successor Indemnification. If the Company or any of its successors
or assignees consolidates with or merges into any other person or entity and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the
successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board as in effect immediately before such transaction, whether such obligations are contained in the Company’s
bylaws, the Company’s certificate of incorporation, or elsewhere, as the case may be. 
 5.4 Expenses of Counsel.
In the event of a transaction which is a Sale of the Company (as defined in the Voting Agreement), the reasonable fees and disbursements, not to exceed $50,000, of one counsel for the Major Investors as selected by holders of a majority of
Registerable Securities then held by the Major Investors (“Investor Counsel”), in their capacities as stockholders, shall be borne and paid by the Company. At the outset of considering a transaction which, if consummated would
constitute a Sale of the Company, the Company shall obtain the ability to share with the Investor Counsel (and such counsel’s clients) and shall share the confidential information (including, without limitation, the drafts of memoranda of
understanding (but not necessarily all drafts thereof), letters of intent (but not necessarily all drafts thereof), and definitive transaction documents and related noncompete, employment, consulting and other compensation agreements and plans)
pertaining to and memorializing any of the transactions which, individually or when aggregated with others would constitute the Sale of the Company. The Company shall be obligated to share (and cause the Company’s counsel and investment bankers
to share) copies of definitive agreements with respect to such transaction when distributed to the Company’s executives and/or any one or more of the other parties to such transaction(s). In the event that Investor Counsel deems it appropriate,
in its reasonable discretion, to enter into a joint defense agreement or other arrangement to enhance the ability of the parties to protect their communications and other reviewed materials under the attorney client privilege, the Company shall, and
shall direct its counsel to, execute and deliver to Investor Counsel and its clients such an agreement in form and substance reasonably acceptable to Investor Counsel. In the event that one or more of the other party or parties to such transactions
require the clients of Investor Counsel to enter into a confidentiality agreement and/or joint defense agreement in order to receive such information, then the Company shall share whatever information can be shared without entry into such agreement
and shall, at the same time, in good faith work expeditiously to enable Investor Counsel and its clients to negotiate and enter into the appropriate agreement(s) without undue burden to the clients of Investor Counsel. 

5.5 Observer Right. The Company shall allow one representative of Nextech VI Oncology SCSP
(“Nextech”) for so long as Nextech and its Affiliates own not less than 25% of the shares of the Series B Preferred Stock purchased by Nextech under that certain Series B Preferred Stock Purchase Agreement dated as of
March 4, 2020 by the Company and the investors named therein, as subsequently amended, to attend all meetings of the Board in a non-voting observer capacity (the “Observer”) and
shall provide the Observer copies of all notices, minutes, consents, and other materials that it provides to the Board at the same time and in the same manner as provided to the Board. The Observer shall enter into a standard form of confidentiality
agreement with the Company pursuant to which such Observer shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided. The Company reserves the right to withhold any information and to
exclude the Observer from any meeting or portion thereof if the Board reasonably believes that access to 

  
 26 

 
such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel, such information is a highly confidential trade secret or
would be a conflict of interest between such Observer and the Company. 
 5.6 Qualified Small Business Stock. The
Company shall use commercially reasonable efforts to cause the shares of Series B Preferred Stock issued in the First Tranche Closing and the Second Tranche Closing, as each is capitalized term is defined in that certain Series B Preferred Stock
Purchase Agreement entered into between the Company and the investors named therein as of March 4, 2020, as subsequently amended, as well as any shares into which such shares are converted, within the meaning of Section 1202(f) of the
Internal Revenue Code (the “Code”), to constitute “qualified small business stock” as defined in Section 1202(c) of the Code; provided, however, that such requirement shall not be applicable if the Board of
Directors of the Company determines, in its good-faith business judgment, that such qualification is inconsistent with the best interests of the Company. The Company shall submit to its stockholders (including the Investors) and to the Internal
Revenue Service any reports that may be required under Section 1202(d)(1)(C) of the Code and the regulations promulgated thereunder. In addition, within twenty (20) business days after any Investor’s reasonable written request
therefor, the Company shall, at its option, either (i) deliver to such Investor a written statement indicating whether (and what portion of) such Investor’s interest in the Company constitutes “qualified small business stock” as
defined in Section 1202(c) of the Code or (ii) deliver to such Investor such factual information in the Company’s possession as is reasonably necessary to enable such Investor to determine whether (and what portion of) such
Investor’s interest in the Company constitutes “qualified small business stock” as defined in Section 1202(c) of the Code. Nothing in this Section 5.6 or in any written statement that is delivered
pursuant to this Section 5.6 constitutes a representation, warranty or covenant that the Company has been, is or will be engaged in a “qualified trade or business” within the meaning of Code Section 1202(e)(3) or has met, meets
or will meet the active business requirement of Code Section 1202(e)(1)(A), and although the representation and warranty in this Section 5.6 are undertaken in good faith, the Company shall not be liable for damages as
the result of any failure of any of its stock to qualify as “qualified small business stock.” 
 5.7 Termination of
Covenants. The covenants set forth in Sections 5.1, 5.2, 5.3, 5.4, 5.5 and 5.6 above shall terminate and be of no further force or effect upon the consummation of the earlier to occur of (a) an
Initial Public Offering, and (b) a Liquidation Event, except that such covenants shall not terminate upon the consummation of a Liquidation Event that is the sale of all or substantially all of the assets of the Company unless approved in
writing by the Preferred Majority; provided further that the provisions of Sections 5.3 and 5.4 hereof will continue after the closing of any Sale of the Company to the extent necessary to enforce the provisions thereof with respect to such
Sale of the Company. 
 6. CFIUS. 

6.1 Notice. If any pre-existing products or services provided by the Company are re-categorized by the U.S. government as critical technologies within the meaning of the Defense Production Act of 1950, as amended, including all implementing regulations thereof (the
“DPA”), or would reasonably be considered to constitute the design, fabrication, development, testing, production or manufacture of critical technologies after a re-categorization of
selected 

  
 27 

 
technologies by the U.S. government, the Company shall provide written notice to each CFIUS Investor reasonably soon after the Company becomes aware of such
re-categorization, and in any event prior to the delivery of a notice pursuant to Section 4.3 above. 

6.2 Filing. If and to the extent: (i) CFIUS requests or requires that any CFIUS Investor or the Company file a
notice or declaration with CFIUS pursuant to the DPA with respect to such CFIUS Investor’s exercise of its right of first refusal set forth in this Section 4 (a “Covered Transaction”) or
(ii) a CFIUS Investor and the Company mutually determine that a filing with CFIUS is required with respect to a Covered Transaction pursuant to 31 C.F.R. Part 801, then in either case: (x) the Company and such CFIUS Investor shall each,
and shall cause its Affiliates to, cooperate with the other parties hereto and shall promptly file a CFIUS filing in the requested form in accordance with the DPA; and (y) the Company and such CFIUS Investor shall each, and each shall cause its
Affiliates to, use commercially reasonable efforts to obtain applicable CFIUS clearances to enable such CFIUS to exercise its rights under Section 4. Notwithstanding anything to the contrary in this Agreement, under no
circumstances shall the Company have an obligation to issue or sell any of its securities to any Investor in violation of Section 721 of the Defense Production Act of 1950, as amended, and all implementing rules and
regulations issued thereunder, including 31 C.F.R. Parts 800-801 (“CFIUS Laws”) or other applicable laws, and no Investor shall have the right to retain any rights set forth herein that
are or become in violation of CFIUS Laws or other applicable laws. 
 6.3 Termination. The covenants set forth in this
Section 6 shall terminate and be of no further force or effect upon the consummation of the earlier to occur of (a) an Initial Public Offering, and (b) a Liquidation Event, except that this Agreement shall not
terminate upon the consummation of all or substantially all of the assets of the Company unless approved in writing by the Preferred Majority. 
 7.
Miscellaneous. 
 7.1 Successors and Assigns. The terms and conditions of this Agreement shall inure to
the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any
rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

7.2 Governing Law. This Agreement will be construed and enforced in accordance with the substantive laws of the State of
Delaware without reference to principles of conflicts of law. EACH PARTY HERETO HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF ANY STATE OR FEDERAL COURT SITTING IN DELAWARE, IN ANY PROCEEDING ARISING OUT OF OR RELATING TO THIS
AGREEMENT AND TO THE RESPECTIVE COURT TO WHICH AN APPEAL OF THE DECISIONS OF ANY SUCH COURT MAY BE TAKEN, AND EACH PARTY AGREES NOT TO COMMENCE, OR COOPERATE IN OR ENCOURAGE THE COMMENCEMENT OF, ANY SUCH PROCEEDING, EXCEPT IN PROCEEDING WILL BE
CONCLUSIVE AND MAY BE ENFORCED IN ANY JURISDICTION BY SUIT IN SUCH A COURT. EACH PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT IT MAY DO SO, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE THEREIN OF SUCH A PROCEEDING. 

  
 28 

 7.3 Counterparts. This Agreement may be executed in any number of
counterparts and signatures may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method, each of which may be executed by
less than all parties, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall constitute one instrument. 

7.4 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement. 
 7.5 Notices. All notices required or permitted hereunder
shall be in writing and shall be deemed effectively given upon the earliest of: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed e-mail or confirmed facsimile if
sent during normal business hours of the recipient, if not, then on the next business day, or (c) one (1) business day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written identification of
receipt; provided that if the sender’s and the recipient’s addresses are not in the same country, two (2) business days after deposit with an internationally recognized overnight courier, specifying next day delivery, with written
identification of receipt. All communications shall be sent, if to the Company, at the address set forth on the signature page hereto, and if to an Investor, at its address as set forth on Exhibit A hereto, or at such other address or contact
information as such party may designate by ten (10) calendar days’ advance written notice to the other parties hereto. 

7.6 Amendments and Waivers. Except as expressly provided herein, any term of this Agreement may be amended, terminated or
waived only with the written consent of (a) the Company and (b) the Preferred Majority, or, following the Initial Public Offering of the Company, the holders of a majority of the Registrable Securities; provided that: (i) no
amendment, termination or waiver of any term under this Agreement shall adversely affect any Investor or group of Investors in a manner that is disproportionate to its holdings of stock relative to the other Investors of the same class or series
unless such amendment, termination or waiver is agreed to in writing by a majority in interest of the disproportionately affected Investor(s); (ii) neither this clause (ii) or Section 5.5 may be amended, terminated or
waived without the written consent of Nextech for as long as Nextech has a right to have an Observer attend meetings of the Board pursuant to Section 5.5; (iii) if the second sentence of
Section 4.5 is amended, terminated or waived pursuant to the provisions of this Section 7.6, and a ROFR Holder purchases New Securities in an offering that is made in connection such amendment,
termination or waiver which would constitute a Waiver Purchase (treating an amendment, waiver or termination of such sentence as if it were a Waiver Purchase for purposes of this sentence), then each ROFR Holder shall have a ROFR Revival Right; and
(iv) no amendment to Section 1(q) shall cause an Investor that is a Major Investor to lose its status as a Major Investor without such Major Investor’s written consent unless such amendment is in connection with the issuance of New
Securities, such Major Investor was offered a right to purchase its Pro Rata Amount of such New Securities (or was offered a right to purchase a lesser amount of such New Securities based on 

  
 29 

 
such Major Investor’s relative holdings of Company equity as compared to the equity holdings of all other Major Investors) and fails to purchase the full amount of such New Securities
offered to it. For the avoidance of doubt, the addition to this Agreement of any new holder of shares of capital stock of the Company (“Capital Stock”) pursuant to the Company’s issuance of such other Capital Stock
regardless of whether such Capital Stock has rights, preferences or privileges that are junior, pari passu or senior to the Capital Stock then held by then current Investors as long as such other or additional shares of Capital Stock have been
authorized and issued in accordance with the Company’s then current Restated Certificate and applicable law, and as long as the addition of such new holder of Capital Stock of the Company (or inclusion of such new shares of Capital Stock) has
been approved as may be required pursuant to Section 2.13 above shall not, in and of itself, be deemed to constitute an amendment or waiver that adversely affects one Investor in a manner that is disproportionate to any
other Investor. Any amendment or waiver effected in accordance with this Section 7.6 shall be binding upon the Holders and each transferee of the Shares (or the Common Stock issuable upon conversion thereof), each future
holder of all such securities, and the Company. Each Holder acknowledges that by the operation of this Section (and pursuant to the terms of this Section), the Preferred Majority will have the right and power to diminish or eliminate all rights of
such Holder under this Agreement. The Company shall give prompt notice of any amendment, modification or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, modification, termination, or
waiver. Notwithstanding anything to the contrary contained in this Agreement, if the Company issues additional shares of Series C Preferred Stock after the date hereof pursuant to the Series C Purchase Agreement, any purchaser of such shares of
Series C Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement and thereafter shall be deemed an “Investor” for all purposes hereunder without the
consent of any party hereto. 
 7.7 Severability. Whenever possible, each provision of this Agreement shall be
interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such
prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. 
 7.8
Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party upon any breach or default of any other party under this Agreement shall impair any such right, power or remedy of such party, nor
shall it be construed to be a waiver of any such breach or default or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other
breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions
or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing or as provided in this Agreement. All remedies, either under this Agreement or by law or otherwise afforded to any
party, shall be cumulative and not alternative. 
 7.9 Entire Agreement. This Agreement (including the exhibits hereto)
constitutes the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties are expressly
canceled. 

  
 30 

 7.10 Further Assurances. At any time or from time to time after the
date hereof, the parties hereto agree to cooperate with each other, and at the request of any such party hereto, to execute and deliver any further instruments or documents and to take all such further action as the other party may reasonably
request in order to evidence or effectuate the consummation of the transactions contemplated hereby and to otherwise carry out the intent of the parties hereunder. 

7.11 Aggregation of Stock. All shares of Company equity held or acquired by a Holder and/or its Affiliates shall be
aggregated together for the purpose of determining the availability of any rights and any obligations under this Agreement, and such affiliated persons may apportion such rights and obligations as among themselves in any manner they deem
appropriate. 
 7.12 WAIVER OF JURY TRIAL. EACH PARTY HERETO AND ANY OTHER PERSON CLAIMING ANY RIGHTS HEREUNDER, HEREBY
IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE ACTIONS OF ANY PARTY HERETO IN THE NEGOTIATION,
ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF. 
 7.13 Amendment and Restatement of Prior Agreement. The Prior
Agreement is hereby amended in its entirety and restated herein. Such amendment and restatement is effective upon the execution of this Agreement by the Company and the requisite Investors as set forth in the Prior Agreement. Upon such execution,
all provisions of, rights granted and covenants made in the Prior Agreement are hereby waived, released and superseded in their entirety and shall have no further force or effect. 

[THIS SPACE LEFT BLANK INTENTIONALLY] 

  
 31 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated
Investors’ Rights Agreement as of the Effective Date. 
  

			
	 COMPANY:

	
	 SILVERBACK THERAPEUTICS, INC.

		
	 By:
	 	 /s/ Laura Shawver

		 	Laura Shawver
		 	President and Chief Executive Officer

 
			
		
	 Address:
	 	 500 Fairview Ave N #600

		 	 Seattle, WA 98109

	 Attention:
	 	 President and Chief Executive Officer

  
 Signature Page to
Silverback Therapeutics, Inc. 
 Amended and Restated Investor’s Rights Agreement (Series C) 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated
Investors’ Rights Agreement as of the Effective Date. 
  

			
	 INVESTORS:

	
	 ORBIMED PRIVATE INVESTMENTS VI, LP

		
	 By:
	 	 OrbiMed Capital GP VI LLC,

		 	 its General Partner

		
	 By:
	 	 OrbiMed Advisors LLC,

		 	 its Managing Member

					
			
		 	 By:
	 	 /s/ Carl Gordon

			
		 	 Name:
	 	 Carl Gordon

			
		 	 Title:
	 	 Member

  
 Signature Page to
Silverback Therapeutics, Inc. 
 Amended and Restated Investor’s Rights Agreement (Series C) 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated
Investors’ Rights Agreement as of the Effective Date. 
  

			
	 INVESTORS:

	
	 U.S. VENTURE PARTNERS XII, L.P.

	 U.S. VENTURE PARTNERS XII-A,
L.P.

		
	 By:
	 	 Presidio Management Group XII, L.L.C.

	 The General Partner of Each

		
	 By:
	 	 /s/ Dale Holladay

		 	Dale Holladay, Attorney-In-Fact

  
 Signature Page to
Silverback Therapeutics, Inc. 
 Amended and Restated Investor’s Rights Agreement (Series C) 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated
Investors’ Rights Agreement as of the Effective Date. 
  

			
	 INVESTORS:

	
	 PRECISION ONCO LIMITED

		
	By:	 	 /s/ Yuan Sun

	Name:	 	Yuan Sun
	Title:	 	Director

  
 Signature Page to
Silverback Therapeutics, Inc. 
 Amended and Restated Investor’s Rights Agreement (Series C) 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated
Investors’ Rights Agreement as of the Effective Date. 
  

									
	INVESTORS:	  		 	
			
	PONTIFAX (ISRAEL)	  		 	PONTIFAX (CHINA) V
	LIMITED PARTNERSHIP	  		 	LIMITED PARTNERSHIP
					
	By:	  	 /s/ Tamar Kariv
	  		 	By:	 	 /s/ Tamar Kariv

					
	Name:	  	 Tamar Kariv
	  		 	Name:	 	 Tamar Kariv

					
	Title:	  	 CEO
	  		 	Title:	 	 CEO

			
	PONTIFAX (CAYMAN) V	  		 	 PONTIFAX LATE STAGE FUND

	LIMITED PARTNERSHIP	  		 	 LIMITED PARTNERSHIP

					
	By:	  	 /s/ Tamar Kariv
	  		 	By:	 	 /s/ Tamar Kariv

					
	Name:	  	 Tamar Kariv
	  		 	Name:	 	 Tamar Kariv

					
	Title:	  	 CEO
	  		 	Title:	 	 Managing Partner

  
 Signature Page to
Silverback Therapeutics, Inc. 
 Amended and Restated Investor’s Rights Agreement (Series C) 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated
Investors’ Rights Agreement as of the Effective Date. 
  

			
	 INVESTORS:

	
	 HUNT PACIFIC, L.P., a Texas Limited Partnership

	 By:
	 	 D.S. Hunt Corp., Its General Partner

	
	 /s/ David S. Hunt

	 David S. Hunt, President

  
 Signature Page to
Silverback Therapeutics, Inc. 
 Amended and Restated Investor’s Rights Agreement (Series C) 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated
Investors’ Rights Agreement as of the Effective Date. 
  

					
	 INVESTORS:

	
	 Nextech VI GP S.à.r.l. as General Partner on behalf of

NEXTECH VI ONCOLOGY SCSP

			
	 By:
	 	 /s/ Dalia Bleyer
	 	 /s/ Philippe Detournay

			
	 Name:
	 	 Dalia Bleyer
	 	 Philippe Detournay

			
	 Title:
	 	 Manager
	 	 Manager

  
 Signature Page to
Silverback Therapeutics, Inc. 
 Amended and Restated Investor’s Rights Agreement (Series C) 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated
Investors’ Rights Agreement as of the Effective Date. 
  

			
	 INVESTORS:

	
	 THE BOARD OF TRUSTEES OF THE LELAND

	 STANFORD JUNIOR UNIVERSITY (DAPER I)

		
	By:	 	 /s/ Sabrina Liang

		 	Sabrina Liang, Director
	
	 THE BOARD OF TRUSTEES OF THE LELAND

	 STANFORD JUNIOR UNIVERSITY (SBST)

		
	By:	 	 /s/ Sabrina Liang

		 	Sabrina Liang, Director

  
 Signature Page to
Silverback Therapeutics, Inc. 
 Amended and Restated Investor’s Rights Agreement (Series C) 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated
Investors’ Rights Agreement as of the Effective Date. 
  

									
	 INVESTORS:

			
	EcoR1 Capital Fund, L.P.	 		 	 EcoR1 Capital Fund Qualified, L.P.

	By:	  	EcoR1 Capital, LLC, its General Partner	 		 	By:	 	EcoR1 Capital, LLC, its General Partner
					
	By:	  	 /s/ Oleg Nodelman
	 		 	By:	 	 /s/ Oleg Nodelman

	Name:	  	Oleg Nodelman,	 		 	Name:	 	Oleg Nodelman,
	Title:	  	Manager	 		 	Title:	 	Manager

  

			
	
	 EcoR1 Venture Opportunity Fund, L.P.

	 By:
	 	 Biotech Opportunity GP, LLC, its General Partner

		
	By:	 	 /s/ Oleg Nodelman

	Name:	 	Oleg Nodelman,
	Title:	 	Manager

  
 Signature Page to
Silverback Therapeutics, Inc. 
 Amended and Restated Investor’s Rights Agreement (Series C) 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated
Investors’ Rights Agreement as of the Effective Date. 
  

			
	 INVESTORS:

	
	 BOXER CAPITAL, LLC

		
	By:	 	 /s/ Aaron Davis

	Name:	 	Aaron Davis
	Its:	 	Chief Executive Officer
	
	 MVA INVESTORS, LLC

		
	By:	 	 /s/ Aaron Davis

	Name:	 	Aaron Davis
	Its:	 	Chief Executive Officer

  
 Signature Page to
Silverback Therapeutics, Inc. 
 Amended and Restated Investor’s Rights Agreement (Series C) 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated
Investors’ Rights Agreement as of the Effective Date. 
 INVESTORS: 
  

									
	RA Capital Healthcare Fund, L.P.	 		 	RA Capital NEXUS Fund, L.P.
					
	By:	 	RA Capital Healthcare Fund GP, LLC	 		 	By:	 	RA Capital Nexus Fund GP, LLC
		 	Its General Partner	 		 		 	Its General Partner
					
	By:	 	 /s/ Peter Kolchinsky
	 		 	By:	 	 /s/ Peter Kolchinsky

					
	Name:	 	 Peter Kolchinsky
	 		 	Name:	 	 Peter Kolchinsky

					
	Title:	 	 Manager
	 		 	Title:	 	 Manager

  

			
	BLACKWELL PARTNERS LLC – SERIES A
		
	 By:
	 	 /s/ Abayomi A. Adigun

		
	 Name:
	 	 Abayomi A. Adigun

		 	Investment Manager, DUMAC, Inc.
	 Title:
	 	Authorized Signatory
		
	 By:
	 	 /s/ Jannine M. Lall

		
	 Name:
	 	 Jannine M. Lall

		 	Head of Finance & Controller, DUMAC, Inc.
	 Title:
	 	Authorized Signatory

  
 Signature Page to
Silverback Therapeutics, Inc. 
 Amended and Restated Investor’s Rights Agreement (Series C) 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated
Investors’ Rights Agreement as of the Effective Date. 
 INVESTORS: 
  

									
	 NANTAHALA CAPITAL PARTNERS II

LIMITED PARTNERSHIP
	 		 	 NANTAHALA CAPITAL PARTNERS

LIMITED PARTNERSHIP

					
	By:	 	Nantahala Capital Management, LLC	 		 	By:	 	Nantahala Capital Management, LLC
		 	 Its General Partner
	 		 		 	 Its General Partner

					
	By:	 	 /s/ Wilmot Harkey
	 		 	By:	 	 /s/ Wilmot Harkey

		 	Name: Wilmot Harkey	 		 		 	Name: Wilmot Harkey
		 	Title: Manager	 		 		 	Title: Manager

  
 Signature Page to
Silverback Therapeutics, Inc. 
 Amended and Restated Investor’s Rights Agreement (Series C) 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated
Investors’ Rights Agreement as of the Effective Date. 
 INVESTORS: 
  

											
	BLACKWELL PARTNERS LLC - SERIES A, solely with respect to the portion of its assets for which Nantahala Capital Management, LLC acts as its Investment Manager	 		 	SILVER CREEK CS SAV, L.L.C., solely with respect to the portion of its assets for which Nantahala Capital Management, LLC acts as its Investment Manager
					
	By:	 	 Nantahala Capital Management, LLC
	 		 	By:	 	 Nantahala Capital Management, LLC

		 	 Its Investment Manager
	 		 	Its Investment Manager
					
	By:	 	 /s/ Wilmot Harkey
	 		 	By:	 	 /s/ Wilmot Harkey

	Name:	 	 Wilmot Harkey
	 		 		 	Name:	 	 Wilmot Harkey

	Title:	 	 Manager
	 		 		 	Title:	 	 Manager

  
 Signature Page to
Silverback Therapeutics, Inc. 
 Amended and Restated Investor’s Rights Agreement (Series C) 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated
Investors’ Rights Agreement as of the Effective Date. 
  

													
	INVESTORS:	 		 	
			
	NANTAHALA CAPITAL PARTERNS SI, LP	 	    	 	NCP QR LP
					
	By:	 	Nantahala Capital Management, LLC	 		 	By:	 	Nantahala Capital Management, LLC
		 	Its Investment Manager	 		 	Its Investment Manager
					
	By:	 	 /s/ Wilmot Harkey
	 		 	By:	 	 /s/ Wilmot Harkey

		 	Name:	 	 Wilmot Harkey
	 		 		 	Name:	 	 Wilmot Harkey

		 	Title:	 	 Manager
	 		 		 	Title:	 	 Manager

  
 Signature Page to
Silverback Therapeutics, Inc. 
 Amended and Restated Investor’s Rights Agreement (Series C) 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated
Investors’ Rights Agreement as of the Effective Date. 
  

									
	INVESTORS:	 	    	 	
			
	 Fidelity Select Portfolios: Biotechnology

Portfolio
	 		 	 Fidelity Mt. Vernon Street Trust:

Fidelity Series Growth Company Fund

					
	By:	 	 /s/ Chris Maher
	 		 	By:	 	 /s/ Chris Maher

					
	Name:	 	 Chris Maher
	 		 	Name:	 	 Chris Maher

					
	Title:	 	 Authorized Signatory
	 		 	Title:	 	 Authorized Signatory

  

			
	 Fidelity Growth Company Commingled Pool

	 By:
	 	 Fidelity Management Trust Company,

	 as Trustee

		
	By:	 	 /s/ Chris Maher

		
	Name:	 	 Chris Maher

		
	Title:	 	 Authorized Signatory

  
 Signature Page to
Silverback Therapeutics, Inc. 
 Amended and Restated Investor’s Rights Agreement (Series C) 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated
Investors’ Rights Agreement as of the Effective Date. 
 INVESTORS: 
  

			
	Fidelity Mt. Vernon Street Trust : Fidelity Growth Company K6 Fund
		
	By:	 	 /s/ Chris Maher

		
	Name:	 	 Chris Maher

		
	Title:	 	 Authorized Signatory

  

									
	Fidelity Mt. Vernon Street Trust:	 		 	Fidelity Advisor Series VII: Fidelity
	Fidelity Growth Company Fund	 		 	Advisor Biotechnology Fund
					
	By:	 	 /s/ Chris Maher
	 		 	By:	 	 /s/ Chris Maher

					
	Name:	 	 Chris Maher
	 		 	Name:	 	 Chris Maher

					
	Title:	 	 Authorized Signatory
	 		 	Title:	 	 Authorized Signatory

  
 Signature Page to
Silverback Therapeutics, Inc. 
 Amended and Restated Investor’s Rights Agreement (Series C) 

 EXHIBIT A 

SCHEDULE OF INVESTORS 
  

			
	 OrbiMed Private Investments VI, LP

601 Lexington Avenue, 54th Floor
 New York, NY 10022-4629

Attention: General Counsel
  

Celgene Corporation
 c/o Bristol Myers Squibb Company

430 E. 29th St., 14th Floor
 New York, NY 10016

Attention: Corporate Secretary Office
  

Alexandria Venture Investments, LLC
 385 E. Colorado Blvd,
Suite 299
 Pasadena, CA 91101
 Attention: Monica Beam

 
 U.S. Venture Partners XII, L.P.

1460 El Camino Real, Suite 100
 Menlo Park, CA 94025

Attn: Chief Financial Officer
  

With copy (which shall not constitute notice) to:
 Wilmer Cutler
Pickering Hale and Dorr
 60 State Street
 Boston, MA 02109

Attn: Rosemary G. Reilly
  

U.S. Venture Partners XII-A, L.P.

1460 El Camino Real, Suite 100
 Menlo Park, CA 94025

Attn: Chief Financial Officer
  

With copy (which shall not constitute notice) to:
 Wilmer Cutler
Pickering Hale and Dorr
 60 State Street
 Boston, MA 02109

Attn: Rosemary G. Reilly
	  	 Precision Onco Limited
 Rm2865, 28F, AIA
Central, 1 Connaught Road
 Central, Central, Hong Kong

Attention: Haige Lu, Michael Chuang
  

Pontifax (Israel) V Limited Partnership
 Pontifax
(China) Limited Partnership
 Pontifax (Cayman) Limited Partnership

Pontifax Late Stage Fund Limited
 Partnership

Address for all Pontifax entities:
 14 Shenkar St. Herzelia,
Israel
 Attention: Ran Nussbaum
  

with a copy (which shall not constitute notice) to:

Horn & Co., Law Offices
 Amot Investments Tower, 2
Weizmann St., 24th Floor
 Tel-Aviv 6423902, Israel

Attn: Yuval Horn, Adv.
  

Meritz NS Global Bio Fund
 Korean Partnership

203, 50, Seosomun-ro 11-gil, Jung-gu, Seoul,

04515 Rep. of Korea
 Attention: Kiel Kim, Ian Heo

 
 Hunt Pacific, L.P.

2101 Cedar Springs Road, Suite 600
 Dallas, Texas 75201

Attention: David S. Hunt
  

Colt Silverback Partners, LLC
 2101 Cedar Springs Road,
Suite #1230
 Dallas, TX 75201
 Attn: Darren
Blanton

 EXHIBIT A 

SCHEDULE OF INVESTORS (Continued) 
  

			
	 Nextech VI Oncology SCSp
 8 rue Lou
Hemmer, L-1748 Senningerberg
 Grand Duchy of Luxembourg

Contact: Svitlana Dobrovolska
  

The Board of Trustees of the Leland Stanford
 Junior
University (DAPER I)
 Stanford Management Company
 635
Knight Way
 Stanford, CA 94305-7297
 Attn: Direct
Investments
  
 The Board of Trustees of the Leland Stanford

Junior University (SBST)
 Stanford Management Company

635 Knight Way
 Stanford, CA 94305-7297

Attn: Direct Investments
  

EcoR1 Capital Fund, L.P.
 357 Tehama St #3

San Francisco, CA 94103
 Attention: Oleg Nodelman, Scott
Perlen
  
 EcoR1 Capital Fund Qualified, L.P.

357 Tehama St # 3
 San Francisco, CA 94103

Attention: Oleg Nodelman, Scott Perlen
  

EcoR1 Venture Opportunity Fund, L.P.
 357 Tehama St # 3

San Francisco, CA 94103
 Attention: Oleg Nodelman, Scott
Perlen
	  	 Boxer Capital, LLC
 11682 El Camino
Real
 Suite 320, San Diego, CA 92130
 Attention: Aaron
Davis
  
 MVA Investors, LLC

11682 El Camino Real
 Suite 320, San Diego, CA 92130

Attention: Aaron Davis
  

Nantahala Capital Partners II Limited

Partnership
 Legal Entity Name and Address:

Nantahala Capital Partners II Limited
 Partnership

130 Main St. 2nd Floor
 New Canaan, CT 06840

Notifications:
 Contact: Operations Team

 
 Nantahala Capital Partners Limited

Partnership
 Legal Entity Name and Address:

Nantahala Capital Partners II Limited
 Partnership

130 Main St. 2nd Floor
 New Canaan, CT 06840

Notifications:
 Contact: Operations
Team

 EXHIBIT A 

SCHEDULE OF INVESTORS (Continued) 
  

			
	 Blackwell Partners LLC - Series A
 Legal
Entity Name and Address:
 Blackwell Partners LLC - Series A

280 South Mangum Street, Suite 210
 Durham, NC 27701

Notifications:
 Contact: Operations Team; Jannine Lall

Copy to legal address above and investment
 manager below for
physical.
  
 Silver Creek CS SAV, L.L.C.

Legal Entity Name and Address:
 Silver Creek CS SAV, L.L.C.

1301 5th Avenue, 40th Floor
 Seattle, WA 98101

Notifications:
 Contact: Operations Team(s)

Copy to legal address above and investment
 manager below for
physical.
 Nantahala Capital Management, LLC
 130 Main St. 2nd
Floor
 New Canaan, CT 06840
  

Nantahala Capital Partners SI, LPNCP QR 

LP
 Legal Entity Name and Address:

Nantahala Capital Partners SI, LP
 130 Main St. 2nd Floor

New Canaan, CT 06840
 Notifications:

Contact: Operations Team
 Copy to legal address for physical.

 
 RA Capital Healthcare Fund, L.P.

200 Berkeley St 18th floor
 Boston, MA 02116

Attention: General Counsel
	  	 RA Capital NEXUS Fund, L.P.
 200 Berkeley
St 18th floor
 Boston, MA 02116
 Attention: General Counsel

 
 BLACKWELL PARTNERS LLC -

SERIES A
 Blackwell Partners LLC - Series A

280 S. Mangum Street
 Suite 210

Durham, NC 27701
 Attn: Jannine Lall

 
 Fidelity Select Portfolios: Biotechnology

Portfolio
 Mag & Co.

c/o Brown Brothers Harriman & Co.
 Attn: Corporate
Actions /Vault
 140 Broadway
 New York, NY 10005

 
 Fidelity Mt. Vernon Street Trust:

Fidelity Series Growth Company Fund
 Mag & Co.

do Brown Brothers Harriman & Co.
 Attn: Corporate Actions
/Vault
 140 Broadway
 New York, NY 10005

 
 Fidelity Growth Company Commingled Pool

Mag & Co.
 do Brown Brothers Harriman & Co.

Attn: Corporate Actions /Vault
 140 Broadway

New York, NY 10005

 EXHIBIT A 

SCHEDULE OF INVESTORS (Continued) 
  

			
	 Fidelity Mt. Vernon Street Trust: Fidelity

Growth Company K6 Fund
 BNY MELLON

ONE BNY MELLON CENTER
 500 GRANT STREET AIM 151-2700
 PITTSBURGH, PA 15258
  

Fidelity Mt. Vernon Street Trust:
 Fidelity Growth
Company Fund
 BNY MELLON
 ONE BNY MELLON CENTER

500 GRANT STREET AIM 151-2700

PITTSBURGH, PA 15258
  

Fidelity Advisor Series VII: Fidelity
 Advisor
Biotechnology Fund
 State Street Bank & Trust
 PO
Box 5756
 Boston, Massachusetts 02206
 Attn: Bangle &
Co fbo Fidelity
 Advisor Series VII:
 Fidelity Advisor

Biotechnology FundEX-4.3

 Exhibit 4.3 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR
THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE
COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 
 WARRANT TO PURCHASE COMMON STOCK 

 

			
	Company:	  	SILVERBACK THERAPEUTICS, INC., a Delaware corporation
	Number of Shares of Common Stock:	  	That number of Shares of Common Stock which Holder is entitled to purchase pursuant to Section 1.7.
	Warrant Price:	  	$0.62 per share, which is based on the most recent 409A valuation report of the Company’s Common Stock reviewed and accepted by the Board of Directors of the Company dated May 31, 2016.
	Issue Date:	  	November 21, 2016
	Expiration Date:	  	November 21, 2026 See also Section 5.1(b).
	Credit Facility:	  	This Warrant to Purchase Common Stock (as the same may from time to time be amended, modified, supplemented or restated, the “Warrant”) is issued in connection with that certain Loan and Security Agreement of
even date herewith between Silicon Valley Bank and the Company (as the same may from time to time be amended, modified, supplemented or restated, the “Loan Agreement”).

 THIS WARRANT CERTIFIES THAT, for good and valuable consideration, SILICON VALLEY BANK (together with any
successor or permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase the number of fully paid and non-assessable
shares (the “Shares”) of the above-stated common stock (the “Common Stock”) of the above-named company (the “Company”) at the above-stated Warrant Price, all as set forth above
and as adjusted pursuant to Section 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. Reference is made to Section 5.4 of this Warrant whereby Silicon Valley Bank shall transfer this
Warrant to its parent company, SVB Financial Group. 
 SECTION 1 EXERCISE. 

1.1 Method of Exercise. Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to the
Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in

 
Section 1.2, a check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company in
the Company’s reasonable discretion for the aggregate Warrant Price for the Shares being purchased. 
 1.2 Cashless Exercise. On
any exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner as specified in Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares equal to
the value of this Warrant, or portion hereof as to which this Warrant is being exercised. Thereupon, the Company shall issue to the Holder such number of fully paid and non-assessable Shares as are computed
using the following formula: 
 X = Y(A-B)/A 

where: 
  

			
	X =	  	the number of Shares to be issued to the Holder;
		
	Y =	  	the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate Warrant Price);
		
	A =	  	the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and
		
	B =	  	the Warrant Price.

 1.3 Fair Market Value. If the Company’s Common Stock is then traded or quoted on a nationally
recognized securities exchange, inter-dealer quotation system or over-the-counter market (a “Trading Market”), the fair market value of a Share
shall be the closing price or last sale price of a share of Common Stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Company’s
Common Stock is not traded in a Trading Market, the Board of Directors of the Company shall determine the fair market value of a Share in its reasonable judgment. 

1.4 Delivery of Certificate and New Warrant. Within a reasonable time after Holder exercises this Warrant in the manner set forth in
Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor
representing the Shares not so acquired. 
 1.5 Replacement of Warrant. On receipt of evidence reasonably satisfactory to the Company
of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form, substance and amount to the Company or, in the case of mutilation,
on surrender of this Warrant to the Company for cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount. 

  
 2 

 1.6 Treatment of Warrant Upon Acquisition of Company. 

(a) Acquisition. For the purpose of this Warrant, “Acquisition” means any transaction or series of related
transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company (ii) any merger or consolidation of the Company into or with another person or entity (other than
a merger or consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior to such merger, consolidation or
reorganization, own less than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation or reorganization; or (iii) any sale or other transfer by the
stockholders of the Company of shares representing at least a majority of the Company’s then-total outstanding combined voting power; provided that a transaction or series of related transactions shall not constitute an Acquisition if:
(x) its sole purpose is to change the state of the Company’s incorporation; (y) it is solely a transfer of securities to an underwriter of the Company’s securities in connection with an IPO; or (z) it is solely for bona fide
financing purposes in which cash is received by the Company, or indebtedness of the Company is cancelled or converted, or a combination thereof. 

(b) Treatment of Warrant at Acquisition. In the event of an Acquisition in which the consideration to be received by the Company’s
stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “Cash/Public Acquisition”), and the fair market value of one Share as determined in accordance with
Section 1.3 above would be greater than the Warrant Price in effect on such date immediately prior to such Cash/Public Acquisition, and Holder has not exercised this Warrant pursuant to Section 1.1 above as to all Shares, then this Warrant
shall automatically be deemed to be cashless exercised pursuant to Section 1.2 above as to all Shares effective immediately prior to and contingent upon the consummation of a Cash/Public Acquisition. In connection with such cashless exercise,
Holder shall be deemed to have restated each of the representations and warranties in Section 4 of the Warrant as the date thereof and the Company shall promptly notify the Holder of the number of Shares (or such other securities) issued upon
exercise. In the event of a Cash/Public Acquisition where the fair market value of one Share as determined in accordance with Section 1.3 above would be less than the Warrant Price in effect immediately prior to such Cash/Public Acquisition,
then this Warrant will expire immediately prior to the consummation of such Cash/Public Acquisition. 
 (c) Upon the closing of any
Acquisition other than a Cash/Public Acquisition defined above, the acquiring, surviving or successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property
as would have been paid for the Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance
with the provisions of this Warrant. 
 (d) As used in this Warrant, “Marketable Securities” means securities
meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended

  
 3 

 
(the “Exchange Act”), and is then current in its filing of all required reports and other information under the Act and the Exchange Act; (ii) the class and series of
shares or other security of the issuer that would be received by Holder in connection with the Acquisition were Holder to exercise this Warrant on or prior to the closing thereof is then traded in Trading Market, and (iii) following the closing
of such Acquisition, Holder would not be restricted from publicly re-selling all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise
or convert this Warrant in full on or prior to the closing of such Acquisition, except to the extent that any such restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y) does not extend beyond
six (6) months from the closing of such Acquisition. 
 1.7 Number of Shares of Common Stock Granted to Holder. On the initial
Funding Date of the initial Term Loan Advance, the number of Shares for which this Warrant shall be exercised shall be determined as follows: one-half of one percent (0.50%) of the original principal amount of
such Term Loan Advance divided by the Warrant Price. In furtherance of the foregoing sentence, such number of Shares for which this Warrant shall be exercisable shall be increased for each successive Term Loan Advance in an amount equal to one-half of one percent (0.50%) of the original principal amount of such successive Term Loan Advance divided by the Warrant Price (which such number of Shares would be less any Shares for which this Warrant has
been previously exercised); provided that in no event shall the total amount of Shares for which this Warrant is exercisable exceeds $5,000,000 multiplied by one-half of one percent (0.50%), divided by the
Warrant Price. For purposes of clarification only, if the aggregate original principal amount of Term Loan Advances advanced to the Company is $5,000,000, then the number of Shares for which this Warrant is exercisable shall be 40,322 Shares
(i.e., 0.005 multiplied by $5,000,000, then divided by the Warrant Price). Capitalized terms used but not defined in this Section 1.7 shall have the meanings given to them in the Loan Agreement. 

SECTION 2 ADJUSTMENTS TO THE SHARES AND WARRANT PRICE. 

2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the outstanding shares of the Common
Stock payable in securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and property which Holder would
have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding shares of the Common Stock by reclassification or otherwise into a greater number of shares, the
number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Common Stock are combined or consolidated, by reclassification or otherwise, into a
lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased. 

2.2 Reclassification, Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding shares of the Common Stock
are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of such event, this Warrant will be exercisable for the number, class
and series of Company securities that Holder would have 

  
 4 

 
received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to time in accordance with the provisions of this
Warrant. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations substitutions, replacements or other similar events. 

2.3 Intentionally Omitted. 

2.4 Intentionally Omitted. 

2.5 No Fractional Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be issued
shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the
fractional interest by (i) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the then-effective Warrant Price. 

2.6 Notice/Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Common Stock and/or number of Shares, the Company,
at the Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, class and/or number of Shares and facts upon which such adjustment is based. The Company shall, upon written
request from Holder, furnish Holder with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, class and number of Shares in effect upon the date of such adjustment. 

SECTION 3 REPRESENTATIONS AND COVENANTS OF THE COMPANY. 

3.1 Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows: 

(a) The initial Warrant Price referenced on the first page of this Warrant is not greater than the price per share at which shares of Company
Common Stock or options to purchase shares of Company Common Stock were issued immediately prior to the Issue Date hereof. 
 (b) All Shares
which may be issued upon the exercise of this Warrant shall, upon issuance, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and encumbrances except for restrictions on
transfer provided for herein or under applicable federal and state securities laws. The Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued capital stock such number of securities
as will be sufficient to permit the exercise in full of this Warrant. 
 (c) The Company’s capitalization table attached hereto as
Schedule 1 is true and complete, in all material respects, as of the Issue Date. 

  
 5 

 3.2 Notice of Certain Events. If the Company proposes at any time to: 

(a) declare any dividend or distribution upon the outstanding shares of the Company’s stock, whether in cash, property, stock, or other
securities and whether or not a regular cash dividend; 
 (b) offer for subscription or sale pro rata to the holders of the outstanding
shares any additional shares of any class or series of the Company’s stock (other than pursuant to contractual pre-emptive rights); 

(c) effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the
Common Stock; 
 (d) effect an Acquisition or to liquidate, dissolve or wind up; or 

(e) effect an initial, underwritten offering and sale of its securities to the public pursuant to an effective registration statement under
the Act (the “IPO”); 
 then, in connection with each such event, the Company shall give Holder: 

(1) in the case of the matters referred to in (a) and (b) above, at least seven (7) Business Days prior written
notice of the earlier to occur of the effective date thereof or the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of outstanding shares of the Common Stock
will be entitled thereto) or for determining rights to vote, if any; 
 (2) in the case of the matters referred to in
(c) and (d) above at least seven (7) Business Days prior written notice of the date when the same will take place (and specifying the date on which the holders of outstanding shares of the Common Stock will be entitled to exchange their
shares for the securities or other property deliverable upon the occurrence of such event and such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with such event giving rise to the
notice); and 
 (3) with respect to the IPO, at least seven (7) Business Days prior written notice of the date on which
the Company proposes to file its registration statement in connection therewith. 
 Company will also provide information reasonably requested by Holder
that is reasonably necessary to enable Holder to comply with Holder’s accounting or reporting requirements. 
 SECTION 4
REPRESENTATIONS, WARRANTIES OF THE HOLDER. 
 The Holder represents and warrants to the Company as follows: 

4.1 Purchase for Own Account. This Warrant and the Shares to be acquired upon exercise of this Warrant by Holder are being acquired for
investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of acquiring this
Warrant or the Shares. 

  
 6 

 4.2 Disclosure of Information. Holder is aware of the Company’s business affairs
and financial condition and has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities.
Holder further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the
Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access. 

4.3 Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities involves substantial
risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and has such
knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the
Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons. 

4.4 Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated under the
Act. 
 4.5 The Act. Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered under
the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. Holder understands that this Warrant and the Shares issued
upon any exercise hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available. Holder is
aware of the provisions of Rule 144 promulgated under the Act. 
 4.6 Market Stand-off
Agreement. The Holder agrees that the Shares shall be subject to the Market Standoff provisions in Section 2.10 of the Investor Rights Agreement entered into between the Company and certain of the holders of the Company’s securities as
of April 1, 2016, as such may be amended from time to time pursuant to the terms thereof, or similar agreement. 
 4.7 No Voting
Rights. Holder, as a Holder of this Warrant, will not have any voting rights until the exercise of this Warrant. 

  
 7 

 SECTION 5 MISCELLANEOUS. 

5.1 Term and Automatic Conversion Upon Expiration. 

(a) Term. Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part at any time and from
time to time on or before 6:00 PM, Pacific time, on the Expiration Date and shall be void thereafter. 
 (b) Automatic Cashless Exercise
upon Expiration. In the event that, upon the Expiration Date, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in
effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the
Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued upon such exercise to Holder. 

5.2 Legends. The Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted
with a legend in substantially the following form: 
 THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE COMMON STOCK ISSUED BY THE ISSUER TO SILICON VALLEY BANK DATED NOVEMBER 21, 2016, MAY
NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 

5.3 Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant (and the securities
issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part except in compliance with applicable federal and state securities laws by the transferor and the transferee (including,
without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of counsel if the
transfer is to SVB Financial Group (Silicon Valley Bank’s parent company) or any other affiliate of Holder, provided that any such transferee is an “accredited investor” as defined in Regulation D promulgated under the Act.
Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144 promulgated under the Act. 

  
 8 

 5.4 Transfer Procedure. After receipt by Silicon Valley Bank of the executed Warrant,
Silicon Valley Bank will transfer all of this Warrant to its parent company, SVB Financial Group. By its acceptance of this Warrant, SVB Financial Group hereby makes to the Company each of the representations and warranties set forth in
Section 4 hereof and agrees to be bound by all of the terms and conditions of this Warrant as if the original Holder hereof. Subject to the provisions of Section 5.3 and upon providing the Company with written notice, SVB Financial Group
and any subsequent Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable directly or indirectly, upon conversion of the Shares, if any) to any transferee, provided, however,
in connection with any such transfer, SVB Financial Group or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name, address and taxpayer identification number of the transferee and Holder
will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable); and provided further, that any subsequent transferee other than SVB Financial Group shall agree in writing with the Company to be bound by all
of the terms and conditions of this Warrant. Notwithstanding any contrary provision herein, at all times prior to the IPO, Holder may not, without the Company’s prior written consent, transfer this Warrant or any portion hereof, or any Shares
issued upon any exercise hereof, or any shares or other securities issued upon any conversion of any Shares issued upon any exercise hereof, to any person or entity who directly competes with the Company, except in connection with an Acquisition of
the Company by such a direct competitor. 
 5.5 Notices. All notices and other communications hereunder from the Company to the
Holder, or vice versa, shall be deemed delivered and effective (i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered or certified
mail, postage prepaid, (iii) upon actual receipt if given by facsimile or electronic mail and such receipt is confirmed in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier
service, courier fee prepaid, in any case at such address as may have been furnished to the Company or Holder, as the case may be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section 5.5.
All notices to Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise: 

SVB Financial Group 
 Attn:
Treasury Department 
 3003 Tasman Drive, HC 215 

Santa Clara, California 95054 

  
 9 

 Notice to the Company shall be addressed as follows until Holder receives notice of a change
in address: 
 Silverback Therapeutics, Inc. 

Attn: Peter Thompson, Chief Executive Officer 

500 Fairview Ave N 
 Seattle,
Washington 98109 
 Telephone:
                                     

Facsimile:
                                     

Email:
                                     

5.6 Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular
instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 

5.7 Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the
party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 

5.8 Counterparts; Facsimile/Electronic Signatures. This Warrant may be executed in counterparts, all of which together shall constitute
one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original signature page with regards to any agreement subject to the terms hereof or any amendment thereto. 

5.9 Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of California, without
giving effect to its principles regarding conflicts of law. 
 5.10 Headings. The headings in this Warrant are for purposes of
reference only and shall not limit or otherwise affect the meaning of any provision of this Warrant. 
 5.11 Business Days.
“Business Day” is any day that is not a Saturday, Sunday or a day on which Silicon Valley Bank is closed. 
 [Remainder of
page left blank intentionally] 
 [Signature page follows] 

  
 10 

 IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Common Stock to be
executed by their duly authorized representatives effective as of the Issue Date written above. 
  

			
	 “COMPANY”
  

SILVERBACK THERAPEUTICS, INC.

		
	By:	 	/s/ Peter A. Thompson
		 	Name: Peter A. Thompson
		 	Title: Acting President and Chief Financial Officer

  

			
	 “HOLDER”
  

SILICON VALLEY BANK By:

			
		
	By:	 	/s/ Jackie Spencer

			
		
	Name:	 	 Jackie Spencer

		 	(Print)

			
	Title:	 	Director

  
 [Signature Page to
Silverback – SVB Warrant to Purchase Common Stock] 

 APPENDIX 1 

NOTICE OF EXERCISE 
 1.
The undersigned Holder hereby exercises its right purchase                      shares of the Common Stock of Silverback Therapeutics, Inc.
(the “Company”) in accordance with the attached Warrant To Purchase Common Stock, and tenders payment of the aggregate Warrant Price for such shares as follows: 

 

	 	☐	 check in the amount of
$                 payable to order of the Company enclosed herewith 

  

	 	☐	 Wire transfer of immediately available funds to the Company’s account 

 

	 	☐	 Cashless Exercise pursuant to Section 1 .2 of the Warrant 

 

	 	☐	 Other [Describe] 

2. Please issue a certificate or certificates representing the Shares in the name specified below: 

 

			
	
	  

		  	Holder’s Name
	
	  

	
	  

		  	(Address)

 3. By its execution below and for the benefit of the Company, Holder hereby restates each of the
representations and warranties in Section 4 of the Warrant to Purchase Common Stock as of the date hereof. 
  

			
	HOLDER:
	
	  

		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

		
	(Date):

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]